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Introduction
High-cost health interventions including pharmaceuticals and medical 
technologies are becoming more and more available in Thailand, 
thereby increasing public and patient expectations. However, due to 
limited resources, the government cannot make all of those interventions 
available to the population. This indicates the need to search for ways of 
using existing budgets more efficiently, including setting priorities on which 
interventions should be publicly funded.
Yet, priority setting of health interventions is one of the most challenging 
and difficult issues faced by health policy decision-makers around the world. 
It is especially relevant and important in low- and middle-income countries 
(LMIC), where health needs are large and resources are very limited. The 
priority setting process is said to be further complicated by several factors, 
including political instability, weak institutions, the involvement of multiple 
players in the process with sometimes conflicting objectives, a lack of 
evidence on the performance of interventions – all issues that hamper 
systematic priority setting [1, 2]. As a result, priority setting decisions in LMIC 
including Thailand is often history-based and ad-hoc, and relies often on 
policy makers’ opinions, the preferences of international funding agencies, 
lobbying and political pressure [3].
Recent decades have witnessed the development of various explicit 
criteria to rationalise the priority setting process. Most importantly, 
and a cornerstone of many national disease programmes, is the capacity 
of interventions to maximize general population health, i.e. its effectiveness 
[4, 5]. Others have proposed cost and cost-effectiveness as important 
criteria to guide choices in health care – these criteria explicitly recognise 
the economic constrains of the provision of health care, and imply that 
only those interventions that show value for money should be publicly 
Towards rational priority setting in health care
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financed [6-9]. However, the sole use of criteria ‘effectiveness’ or ‘efficiency’ 
falls short to capture other important aspects of health care that 
guide the choice of interventions. Ethical concerns (e.g. preferences 
of society to giving priority to interventions that target vulnerable 
populations like the severely ill, the poor, or the very young) or 
practical considerations (like availability of trained health workers [10]) 
may be equally important, or should at least be considered (Figure 1). 
Priority setting on the basis of only one or two criteria are criticised as 
oversimplified technical solutions’ and to inadequately reflect the complex 
process of priority setting [11-14]. They are therefore unlikely to be acceptable 
for most policy makers in many countries [3, 5, 15-17] including in Thailand 
[14, 18].
Decision-maker
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Figure 1 Ad hoc priority setting and rational priority setting
Source: Baltussen R, Niessen L (2006) Priority setting of health interventions: the need for multi-criteria decision analysis. Cost 
Effectiveness and Resource Allocation 4: 14. 
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Several scholars have recognised this and proposed alternative decision 
criteria that take into account other concerns, including severity of 
disease (e.g. the ‘proportional shortfall’ method by Stolk et al [19]) or age 
(‘fair innings’ argument by Willams [20]). Musgrove [21] proposed 
a sequence on the use of economic efficiency criteria (public goods, 
externalities, catastrophic cost, and cost-effectiveness), ethical (poverty, 
horizontal and vertical equity, and the rule of rescue), and political 
criteria, in selecting which health intervention should be spent by 
public funds. The use of multiple criteria also trickled through in 
a few national processes on priority setting. For instance, effectiveness, 
efficiency, equity and acceptability were used as criteria to prioritise 
health services in New Zealand [22]. The Dutch Government Committee 
on Choices in Health Care, the so-called Dunning Committee, employed 
four explicit priority criteria, i.e. necessity, effectiveness, efficiency 
and individual responsibility, to determine a basic service package 
[22, 23]. The latter was only partially successful, one of the reasons 
being that the criteria were not well-defined. 
Overall, the above suggest the need for rational approaches in priority 
setting, taking into account a comprehensive set of relevant criteria 
simultaneously.  While this holds relevance in all countries around the 
world, the scope to develop rational priority setting is particularly 
large in  Thai land –  i ts  gover nment  has  recent ly  developed 
institutional arrangements to promote evidence-based medicine 
and rational priority setting through the Health Intervention and 
Technology Assessment Program (HITAP). HITAP was established 
in 2007 as a non-profit organization, coming under the auspices 
of  the Ministr y of  Public Health.  I ts  main responsibi l ity is  to 
assess health intervention as well as social health policy. HITAP 
places emphasis on systematic,  transparent work,  which is  in 
conformity with the current situation of Thailand’s health system 
– it thereby aims to cultivate the public interest and motivate the 
par t ic ipat ion of  a l l  sec tors  in  society  in  order  to  ef f ic ient ly 
distribute and allocate the limited resources to fulfill the public 
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objectives [24]. The establishment of HITAP was only the direct lead to the 
conduct of the present thesis, and the research questions as described 
below.
Against the abovementioned background, the main research question 
of this thesis is “what is an optimal strategy to prioritise health interventions 
in Thailand?” 
There are three sub-questions:
1. What is the current situation of priority setting of health interventions 
 in LMIC?
2. What is the implementation process of multi-criteria decision analysis 
 (MCDA) in Thailand?, more specifically, a) how to define priority 
 setting criteria?, b) how to rank order health interventions?, and c) what 
 are the challenges in the implementation process of MCDA?
3. How is MCDA best used for priority setting in Thailand?
Research questions
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Figure 2 Overview of outline of the thesis by research questions
What is an optimal strategy to prioritise
health interventions in Thailand?
Sub-question 1:
What is the current situation in 
priority setting in low-and 
middle-income countries?
Sub-question 2:
What is the implementation
process of MCDA in
Thailand?
Sub-question 3:
How is MCDA best used for
priority setting in Thailand?
Chapter 2, 3 Chapter 8, 9Chapter 4-7
Chapter 2 replies to the research sub-question 1, and provides an overview 
of all empirical studies on priority setting using multiple criteria in 
LMIC. We systematically reviewed empirical priority setting studies in 
LMIC that were published from January 1997 to October 2008 in 
English. Eighteen studies were identified and classified according to 
their characteristics (i.e. country(-ies) where the studies were conducted, 
area of prioritisation, decision-making level(s), and study objectives), 
and methodological approaches (i.e. which type of respondents 
(or stakeholders) was involved, how criteria were identified, which 
criteria were identified, how preferences for the criteria were elicited, 
and how results were presented).
This introductory chapter continues with an outline on how the different 
chapters address the stated research sub-questions and describes 
their contents (Figure 2). 
Outline of the thesis
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Chapter 3 also replies to the research sub-question 1. This chapter 
presents a study that reports on a single criterion for priority setting 
only, i.e. the economic impact of a disease, and thereby provides insufficient 
information for adequate priority setting. On the basis of these two 
chapters, I developed the conceptual framework to use in the following 
chapters. 
Chapter 4 – 6 report on the use of multi-criteria decision analysis 
(MCDA) to set priorities in HIV/AIDS control and the universal coverage 
health benefit package. These chapters responds to the research 
sub-question 2.
The chapters all use the same framework of MCDA. MCDA is defined 
as ‘a set of methods and approaches to aid decision-making, where 
decisions are based on more than one criterion, which make explicit 
the impact of decision of all the criteria applied and the relative 
importance attached to them’ [25].  MCDA is illustrated in Figure 1. 
We choose MCDA because it encompasses a broad range of different 
approaches, and allows decision-makers to identify and consider a set 
of criteria simultaneously – it  thereby responds to the above 
mentioned limitations of present approaches to priority setting. 
M C D A  i n v o l v e s  t h e  e s t a b l i s h m e n t  o f  a  p a n e l  o f  r e l e v a n t 
stakeholders, the identification of a comprehensive set of criteria by 
the panel, and the assessment of the performance of interventions 
on those criteria in a so-called performance matrix (Table 1). The 
panel then inspects the performance matrix qualitatively or quantitatively 
to  ra n k  o rd e r  i nte r ve nt i o n s.  In a qualitative inspection, the 
panel  s imply interprets  the per formance m a t r i x ,  a n d  m a k e 
implicit judgments on the weights of the various criteria. In a quantitative 
inspection, the panel weigh the different criteria on the basis of 
its relative importance, and multiply the scores by the weights 
to obtain weighed averages for all interventions. Interventions can 
subsequently be rank ordered according to these weighed averages. 
thesis-chapter1.indd   7 4/5/2555   13:12:30
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Table 1 Performance matrix 
A tick indicates the presence of a feature. Severity of disease is shown of a four-scale, with more stars indicating a more severe disease. 
Source: Baltussen R, Niessen L (2006) Priority setting of health interventions: the need for multi-criteria decision analysis. Cost Effectiveness and Resource 
Allocation 4: 14.
Options
Antiretroviral treatment in
HIV / AIDS
Treatment of childhood
pneumonia
Inpatient care for acute
schizophrenia
Plastering for simple fractures
US$200 per DALY
US$20 per DALY
US$2000 per DALY
US$50 per DALY
√
√
15 years and older
0 - 14 years
15 years and older
all
Cost-effectiveness Severity of disease Disease of the poor Age
In the chapters, we employed Discrete Choice Experiments (DCE), to 
determine the relative importance of criteria for priority setting in this 
thesis. In a DCE, respondents choose their preferred option from 
sets of hypothetical scenarios,  each consisting of a bundle of 
criteria that describe the scenario in question. The criteria are constant 
in each scenario,  but the levels  that  descr ibe each cr iter ion 
may vary across scenarios. Analysis of the options chosen by respondents 
in  each scenar io  reveals  the ex tent  to  which each cr i ter ion 
is  impor tant to the decision at hand [26,  27].  Running a DCE 
involves selection of participants, identification of criteria through 
group discussion,  DCE design and administration of  the DCE 
survey.
Case study 1: priority setting of HIV/AIDS interventions in Thailand 
HIV/AIDS is recognized as a leading cause of death and a high burden 
of disease in Thailand [28]. A wide range of preventive, treatment 
and care programmes have been implemented since long to combat 
the disease. Although a sizeable budget for implementation of 
this plan is available - derived from both the Thai government and 
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the International Monetary Fund [29] - there will never be enough 
resources to implement every programme for all target groups at 
full scale. Consequently, Thai policy makers now face the challenge 
on how scarce resources on HIV/AIDS control can be spent more 
wisely.
A range of studies are available to guide Thai policy makers to 
prioritise HIV/AIDS interventions. International estimates are available 
on the effectiveness and cost-effectiveness of HIV/AIDS interventions 
[30-32], and a recent document has systematically reviewed this 
information - in combination with national estimates - to inform 
priorities in HIV/AIDS control [33]. Yet, the analysis falls short to 
include other criteria that may play important roles in decision- 
making such as ethical and social concerns. However, as of yet, there 
is no evidence on the criteria that should guide the priority setting 
of HIV/AIDS programmes in Thailand, including their relative importance. 
Chapter 4 reports on the DCE we carried out to identify the criteria 
and to assess their relative importance for priority setting of HIV/
AIDS interventions in Thailand. The results of this chapter were used 
to prioritise HIV/AIDS interventions in Chapter 5. The chapter illustrates 
the feasibility of MCDA to prioritise HIV/AIDS interventions in Thailand, 
and also shows the usefulness of elaborative process as an integrated 
component of MCDA.
Case study 2: priority setting for health benefit package development in Thailand
Chapter 6 describes the first experience in using MCDA as an overall 
methodological approach for rational and transparent priority setting to 
support the coverage decisions on including health interventions in the 
universal health coverage benefit package in Thailand, in the period 2009-
2010.
The Universal Coverage (UC) scheme is a tax-funded health insurance 
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scheme that offers a comprehensive health benefit package including 
preventive, curative, and rehabilitative health services to eligible 
beneficiaries (approximately 47 millions of Thai population). In 
the past, decisions on the public reimbursement of interventions were 
typically ad-hoc and not transparent: e.g. certain interest groups 
(like politicians, health professionals or industry) could selectively 
advocate new interventions for public reimbursement. Although 
the UC has referred its medicine list from a National List of Essential Drugs 
(NLED) which has been created on the basis of explicit selection 
criteria – known as ISafE score [34] – the NLED focuses only on 
medicines, while the benefit package determines a broader range 
of health interventions than medicines. Decision makers in Thailand 
have recently acknowledged this inadequate process and called 
for more rational, transparent and fair decisions on the public 
reimbursement of interventions to improve population health in the 
country. 
In chapter 7, we evaluate a tool for priority setting - Evidence and 
Value: Impact on Decision-Making (EVIDEM) – in its ability to set priorities 
a c ro s s  a  r a n g e  o f  c o m p e t i n g  i n t e r ve n t i o n s .  W h i l e  E V I D E M 
also employs MCDA as its conceptual framework, it falls short in 
a number of aspect. We propose a stepwise process to identify criteria, 
weights, and rank ordered interventions. The reasoning is illustrated 
with information on the relative importance of criteria as identified in 
the priority setting study on the UC health benefit package.
Chapter 8 capitalises a first set of experiences on the application 
of MCDA in seven LMIC, including Thailand. It shows a variety of criteria 
are used in decision making and addresses the extent to which MCDA 
can guide priority setting in health care. Finally, chapter 9 discusses 
the main findings and responds to the research questions as defined 
in the present chapter. This includes a number of  recommendations to 
improve the priority setting process in Thailand and, more generally, 
research on priority setting. These two chapters address the research 
sub-question 3.
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Objective: To assess and summarize empirical studies on priority setting 
in developing countries. 
Methods: Literature review of empirical studies on priority setting 
of health interventions in developing countries in Medline and EMBASE 
(Ovid) databases. 
Results: Eighteen studies were identiﬁed and classiﬁed according to 
their characteristics and methodological approaches. All studies were 
published after 1999, mostly between 2006 and 2008. Study objectives 
and methodologies varied considerably. Most studies identiﬁed sets of 
relevant criteria for priority setting (17⁄18) and involved different 
stakeholders as respondents (11⁄18). Studies used qualitative (8⁄15) 
or quantitative (3⁄15) techniques, or combinations of these (4⁄15) to elicit 
preferences from respondents. In a few studies, respondents deliberated 
on results (3⁄18). A minority of studies (7⁄18) resulted in a rank 
ordering of interventions. 
Conclusions: This review has revealed an increase in the number of 
empirical studies on priority setting in developing countries in the past 
decade. Methods for explicit priority setting are developing, being reported 
and are veriﬁable and replicable and can potentially lead to solutions for 
ad hoc policy making in health care in many developing countries.
priority setting, developing countries
Abstract 
Keywords
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Introduction
Priority setting of health interventions is one of the most challenging and 
difficult issues faced by health policy decision-makers around the world. 
It is a process that is inevitably value-laden and political (1-5), requiring 
credible evidence, strong and legitimate institutions and fair processes 
(6-9). 
Priority setting is especially important in developing countries, where 
resources are limited and government expenditures on health are less 
than US$20 per capita per year (10). As Kapiriri and Martin (11) argue, 
this is further complicated by: (i) the burden of under development 
in these countries which increases the gap between the health 
needs and resources available to respond to them; (ii) the many 
uncertainties in priority setting because of lack of dependable 
information; (iii) the multiple players with various agendas; (iv) 
few systematic processes for decision-making; and (v) many obstacles 
to implementation such as pol it ical  instabi l i ty,  inadequately 
developed social sectors,  weak institutions and marked social 
inequal i t ies ,  which make the implementat ion of  systematic 
priority setting processes difficult (4). As a result, priority setting in 
developing countries is often ad-hoc or history-based (11, 12). 
There have been a number of international efforts to promote 
rational priority setting by addressing the information gaps, such 
as studies on burden of disease (BoD) (13) and cost-effectiveness 
analysis (CEA) (14, 15). Many such studies have also been carried 
out at the national level, e.g. in Mexico, India, and a set of east 
and northern African countries (16). Although these initiatives 
may have improved the evidence -based for  pr ior ity  sett ing, 
it was also observed that the resulting information is only input 
to complex process of priority setting and that ‘simple technical 
solutions’ are insufﬁcient (15, 17-21). 
In response to this, a growing number of empirical studies have 
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explored more comprehensive approaches to priority setting 
in developing countries in the past decade. For example, researchers 
have tested different strategies to involve all relevant stakeholders 
in the priority setting process (22),  or to identify the relative 
importance of CEA and severity of disease as criteria for priority 
setting (23).  While these studies provide valuable information 
with potential beneﬁt to policy-makers and researchers, a review 
is lacking and the options and limitations of the various approaches 
are difﬁcult to assess. 
We reviewed empirical studies on priority setting of health interventions 
in developing countries, classiﬁed their methodological approaches 
and deﬁned methodological suggestions for future studies. Thus we 
aimed at stimulating discussion on the options and limitations of the 
various approaches. This paper deﬁnes priority setting as the process of 
rank ordering interventions with the aim of informing decision-makers 
on the implementation of these interventions. 
Methods
We carried out a literature search in November 2008 using the Medline 
and EMBASE (Ovid) databases. In a ﬁrst step, we performed a search 
using the following keywords: ‘health’ and ‘priority-setting’ or 
‘prioritization’ or ‘resource allocation’, in combination with the names of 
developing countries according to World Bank 2008 deﬁnitions (24). 
We limited the search to studies published in English available from January 
1997 to October 2008. Next we (i) included studies in the review 
if they reported empirical data to guide future priority setting of 
interventions in health care and (ii) excluded studies from the review 
if  they reported on a single criterion for priority setting only 
(this excludes CEA or BoD studies). In this step, we initially screened study 
abstracts on these criteria and subsequently obtained full-text formats 
for studies that seemed relevant. The ﬁnal inclusion of studies in the 
thesis-chapter2.indd   18 4/5/2555   13:13:31
Setting priorities for health interventions: 
A review
19
Results
The ﬁrst step in the literature search resulted in a total of 1,291 studies. 
In the second step, these studies were initially screened on their 
abstract  and 1,235 studies were excluded.  The remaining 56 
studies were assessed on the basis of the full-text formats and of 
these, 39 articles were excluded. Studies were excluded because, 
e.g.  they merely assessed the participation of stakeholders in 
the priority setting process in the past (e.g. Mubyazi et al. 2007 (25)); 
assessed the relevance of a single criterion in priority setting (e.g. 
Kapiriri et al. 2003 (26)); or assessed the priorities in targeting of diseases 
(thus not interventions) (e.g. Makundi et al. 2005 (27); Rosato et al. 2006 
(28)). A total of 18 studies were ﬁnally selected (Table 1). 
review was based upon a detailed assessment of the full-text formats 
(studies for which no full-text format was available were excluded). All 
abstracts and full-text formats were reviewed independently by both 
authors. In case we disagreed, a discussion was arranged to reach a consensus. 
As step 3, a snowballing technique was used to identify related articles 
in this context and these were also assessed using the same inclusion and 
exclusion criteria. 
We then classiﬁed identiﬁed studies according to four general 
characteristics: i) country(ies) where the studies were conducted; ii) 
area of prioritization; iii) decision-making level(s); and iv) study 
objectives. In addition, we classiﬁed identiﬁed studies according 
to their methodological approaches to the priority setting process. 
Here, we distinguished: i) which type of respondents (or stakeholders) 
was involved; ii) how criteria were identiﬁed; iii) which criteria 
were identiﬁed; iv) how preferences for the criteria were elicited; 
and v) how results were presented. 
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All studies were published after 1999; and 13 in the period 2006–2008. 
Four studies were conducted in Uganda, three in Tanzania, two each in 
South Africa and Ghana and one each in Bosnia-Herzegovina, Ghana, 
Pakistan, Nepal, Argentina, Chile and Thailand. One study researched 
priority setting in three developing countries (Burkina Faso, Ghana 
and Indonesia). The studies covered a wide range of priority setting 
areas: 10 studies prioritised interventions across the healthcare system, 
four studies across several disease areas and four studies concentrated 
on particular disease areas. Most of the identiﬁed studies (14⁄18) focused 
on priority setting at the national level. One study in Tanzania evaluated 
the priority setting process at the district and community levels and 
three considered priority setting process at the institutional level, 
i.e. a hospital. In terms of study objectives, 13 studies primarily aimed at 
identifying criteria for setting priorities in health care. Three studies 
explored the acceptability of using economic evaluation or burden 
of disease information in decision-making health priorities. One study 
examined the introduction of  ‘Accountability for reasonableness’ to 
improve the priority setting process and one study described the 
priority setting process as experienced by stakeholders. 
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Table 1 General characteristics of the 18 included empirical priority setting studies  in developing 
 countries
Study
Teerawattananon and 
Russell (2008)
Vargas and Poblete  
(2008)
Lasry et al. (2008)
Ottersen et al. (2008)
Mshana et al. (2007)
Makundi et al. (2007)
Rubinstein et al. (2007)
Baltussen et al. (2007)
Husain et al. (2007)
Madi et al. (2007)
Kapiriri et al. (2007)
Kapiriri and Martin 
(2006)
Country
Thailand
Chile
South Africa
Tanzania
Tanzania
Tanzania
Argentina
Nepal
Pakistan
Burkina Faso
Ghana
Indonesia
Uganda (Canada 
 and Norway)
Uganda
Characteristics
Area of prioritisation
Several disease area       
(two hypothetical case  
scenarios)
Health system
HIV/AIDS
Health system
Health system
Several disease area
Health system
Several disease area
HIV/AIDS
Safe motherhood  
programme
Health system
Health system
Decision- making  level
National
National
Organization (primary health 
care clinic)
National
District
National
National
National
National
National
Organization (publicly funded 
hospital)
Organization (1,500 bed-public 
hospital)
Objectives
To explore policy actors’ 
 justifications for their decisions on  
 the 2 case scenarios
To examine the introduction of a 
prioritised list of 56 health conditions  
 in Chile by using multiple criteria
To apply the system for HIV/AIDS 
resource allocation to a primary 
healthcare clinic
To explore distributions preferences 
among health planners
To describe an initiative in Tanzania to 
improve priority setting using 
 ‘Accountability for reasonableness’ 
(A4R)
 
To test out a model for priority-setting 
which incorporate both scientific 
evidence and public values
To determine whether economic 
evaluations are considered and used 
by decision-makers and report the  
criteria decision-makers used for 
resource  allocation
To identify the various criteria for 
priority setting, and rank ordering 
health interventions
To identify perceptions of decision- 
makers about the process of resource 
allocation within the National AIDS 
Control Programme
To describe a process to elicit and 
prioritised evaluation needs for safe 
motherhood programme
To describe the process of healthcare 
priority setting and evaluate the 
description using the framework of   
A4R
To describe priority setting process in 
   a hospital and evaluate the 
   description using A4R
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Table 1 (Continued)
Study
Baltussen et al. (2006)
Kapiriri and Norheim 
(2004)
Kapiriri et al. (2004)
Reichenbach (2002)
Hrabač et al. (2000)
Söderlund (1999)
Country
Ghana
Uganda
Uganda
Ghana
Bosnia and 
Herzegovina
South Africa
Characteristics
Area of prioritisation
Several disease area
Health system
Health system
Reproductive health 
(breast and cervical 
cancer)
Health system
Health system
Decision- making  level
National
National
National
National
National
National
Objectives
To identify the various criteria for 
priority setting, and rank ordering 
health interventions
To explore the acceptance of priority 
setting criteria for healthcare system
To establish the relative preferences   
regarding cost-effectiveness of 
interventions and severity of disease 
as main criteria for setting priorities
To examine the influence of political 
and organizational factors on 
national priority setting
To provide an overview of the 
methodology for designing a basic 
package of health entitlements
To define package of essential hospital 
care
Table 2 describes the methodological approaches of the reviewed 
studies. In terms of respondents, 11 studies included more than one 
type of stakeholder (with policy makers being most often included). 
Among these, Makundi et al. (22) involved four types of respondents 
– policy makers, health workers, general population and people living 
with HIV⁄AIDS. Kapiriri et al. (23) included the largest number of respondents 
(413 respondents in Uganda). In terms of approaches to identify criteria, 
10 studies organized group discussions or held interviews. Eight 
studies identiﬁed criteria from a literature review. In terms of identiﬁed criteria, 
cost-effectiveness was the most common impor tant cr iterion 
considered (in 12 of the 17 studies that identiﬁed criteria), followed by 
severity of disease (6⁄17). Other criteria included burden of disease, age 
of target group, poverty reduction, effectiveness⁄beneﬁt of treatment and 
 health effects. 
In terms of eliciting preferences for those criteria, a wide range of approaches 
were used. Eight studies relied solely on (combinations of ) qualitative 
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approaches to elicit participants’ preferences, i.e. by semi-structured 
interviews, group discussions and key informant interviews. Another 
three studies relied solely on quantitative approaches to elicit participants’ 
preferences, i.e. by discrete-choice experiments (DCE) and questionnaires 
involving a rating scale. Four studies combined qualitative and quantitative 
techniques, i.e. Makundi et al. (22) employed individual rating and group 
discussions with a balance sheet to test a model of combining evidence and 
public values in priority-setting and Ottersen et al. (29), Madi et al. (30) and 
Kapiriri et al. (23) used group discussions and questionnaires with rating 
questions to explore respondents’ preferences regarding cost-effectiveness 
and severity of disease. It is to be noted that three studies applied an 
explicit deliberative process to address both quantitative and non-quantitative 
concerns (such as ethical considerations) (22, 29, 30) and they did so to reach 
a consensus by the stakeholders involved. 
In terms of presentation of results, seven studies rank-ordered health 
interventions, three studies rank-ordered identiﬁed criteria, ﬁve studies listed 
the criteria for setting priorities and three studies described participants’ 
views.
Discussion
This review has revealed an increase in the number of empirical studies 
on priority setting in developing countries in the past decade. Methods 
for explicit priority setting are developing, being reported and are 
veriﬁable and replicable. In combination with increasingly available 
evidence of all sorts on diseases and related interventions, these methods 
can potentially be solutions for the ad hoc policy making in health care 
in many developing countries. Yet, most of the studies included in our 
review are small pilot studies and do not include an evaluation of the 
impact of its ﬁnding on actual priority setting. Only when such 
information becomes available, clear recommendations to scale up 
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certain methods can be given. 
Nevertheless, the review allows us to provide a number of suggestions 
on the various aspects of the methodological approaches, on the basis 
of a comparison of our ﬁndings to observations on good priority setting 
practice in the literature. First, most of the studies in this review involved 
policy makers, health workers and general population in their priority 
setting process. This concurs with observations in the literature (31-34) 
that stress the need to involve the views of other stakeholders in addition 
to those of policy makers, especially that of the public, in debates on 
rationing to enhance the legitimacy and fairness of decision-making. We 
therefore suggest future studies to involve relevant stakeholders. 
Secondly, a number of studies involved only a limited number of quantitative 
criteria, whereas observations in the literature (12, 35) stress that many 
other criteria, including medical (e.g. effectiveness of interventions 
and severity of disease) and non-medical (e.g. economic efﬁciency, 
ethical reasons and political circumstances) criteria, may also be 
important and relevant. In addition, some studies identiﬁed criteria 
through literature review, whereas the deﬁnitions of criteria are 
likely to be dependent on culture and perspective. Identifying these 
criteria through focus group discussions with relevant stakeholders is 
probably a better approach to obtain a suitable set of criteria.
 
Thirdly, a number of studies relied solely on quantitative techniques, 
such as DCE, to elicit preferences of respondents. Where the advantage of 
such techniques is that its results can be applied across disease areas 
 ⁄ interventions, their disadvantage is that not all criteria that are 
relevant to priority setting are amenable to quantiﬁcation (not only ethical 
and social acceptability but also more practical considerations like 
intervention complexity) and these techniques then fall short of 
capturing these (36). A number of studies have used qualitative techniques 
such as deliberative processes. Such techniques have the advantage that 
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Table 2 Classification of the 18 included empirical priority setting studies 
 in developing countries according to study methodology
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Table 2 (Continued)
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Table 2 (Continued)
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Table 2 (Continued)
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they are also able to address non-quantitative concerns and that they 
explicitly allow the inclusion of views of different stakeholders (37) and the 
reaching of consensus (36). The disadvantage is that its results are 
only relevant to the disease area⁄interventions under study and cannot be 
generalized across disease areas ⁄ interventions. Our suggestion then, 
is that quantitative techniques such as DCE may be relevant to situations 
where general guidance on priority setting is required and that qualitative 
techniques may be more apt in situations where more speciﬁc decisions 
are required on, e.g. implementation of certain interventions (cf. Murray et 
al. 2000 on the need for generalized vs. highly contextualized CEA). The 
added value of quantitative techniques such as DCE in the latter situation, 
e.g. to make decisions more transparent and explicit, is a topic for further 
research.
Finally, a number of studies presented their results in mere descriptive 
format such as identiﬁed criteria or respondents’ preferences, whereas 
studies on priority setting have the intrinsic aim to rank-order interventions, 
or more speciﬁcally, to identify interventions that should be included or 
excluded from, e.g. public reimbursement (12). To the extent study objectives 
allow, we suggest studies to (also) present the impact of their ﬁndings 
in this respect.
Our study has a number of limitations. First, our review only included 
studies in English and incorporated in Medline and EMBASE (Ovid) 
databases. This may mean that ‘grey literature’ (such as government 
reports, unpublished reports, academic theses and conference 
proceedings) and publications in other languages were not identiﬁed 
from the search. Secondly, our classiﬁcation of study methodologies 
may not be comprehensive and other methodological issues can also 
be important.
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Objective:  The purpose of this study was to develop a cost function model 
to estimate the public treatment cost of shigellosis patients in Thailand.
Methods: This study is an incidence-based cost-of-illness analysis from 
a provider’s perspective. The sample cases in this study were shigellosis 
patients residing in Kaengkhoi District, Saraburi Province, Thailand. All 
diarrhea patients who came to the health-care centers in Kaengkhoi 
District, Kaengkhoi District Hospital and Saraburi Regional Hospital 
during the period covering May 2002 to April 2003 were tested for 
Shigella spp. The sample for our study included all patients with 
culture that confirmed the presence of shigellosis. Public treatment 
cost was defined as the costs incurred by the health-care service 
facilities arising from individual cases. The cost was calculated based 
on the number of services that were utilized (clinic visits, hospitalization, 
pharmaceuticals, and laboratory investigations), as well as the unit 
cost of the services (material, labor and capital costs). The data were 
summarized using descriptive statistics. Furthermore, the stepwise 
multiple regressions were employed to create a cost function, and the 
uncertainty was tested by a one-way sensitivity analysis of varying 
discount rate, cost category, and drug prices.
Results: Cost estimates were based from 137 episodes of 130 patients. 
Ninety-four percent of them received treatment as outpatients. 
One-fifth of the episodes were children aged less than 5 years old. 
The average public treatment cost was US$8.65 per episode based on 
2006 prices (95% CI, 4.79, and 12.51) (approximately US$1 = 38.084 
Thai baht). The majority of the treatment cost (59.3%) was consumed 
by the hospitalized patients, though they only accounted for 5.8% of 
all episodes. The sensitivity analysis on the component of costs and 
drug prices showed a variation in the public treatment cost ranging 
from US$8.29 to US$9.38 (-4.20% and 8.43% of the base-case, 
respectively). The public treatment cost model has an adjusted R2 
of 0.788. The positive predictor variables were types of services 
Abstract 
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(inpatient and outpatient), types of health-care facilities (health center, 
district hospital, regional hospital), and insurance schemes (civil 
servants medical benefit scheme, social security scheme and universal 
health coverage scheme). Treatment cost was estimated for various 
scenarios based on the fitted cost model.
Conclusions: The average public treatment cost of shigellosis in Thailand 
was estimated in this study. Service types, healthcare facilities, and 
insurance schemes were the predictors used to predict nearly 80% 
of the cost. The estimated cost based on the fitted model can be 
employed for hospital management and health-care planning.
cost function, public treatment cost, shigellosis
Keywords
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Introduction
A report made on shigellosis states that the global incidence of diarrhea 
has not declined through the years, although the same study reports 
that mortality resulting from it has declined. For children in developing 
countries under the age of five, the estimated annual mortality rate 
was 4.9 per 1,000 children. Diarrhea caused by Shigella accounts for 
a high percentage of this mortality. It was reported that an estimated 
164.7 million Shigella episodes happened annually worldwide. Sixty-nine 
percent of these episodes involved young children [1]. Thailand is an 
Asian country with 62.2 million population based from 2005 survey. 
Generally, its health problems have shifted from communicable diseases 
to non-communicable diseases, with the notable exception of HIV/AIDS 
[2]. Based on the national reporting system, the incidence of acute 
diarrhea and dysentery was 1536, and 36 per 100,000 populations per 
year, respectively, in 2003. The causes of dysentery were unspecified 
pathogens (81%), culture-confirmed shigellosis (11%), and amoebas 
(8%) [3]. A population-based surveillance study conducted during 
2000 to 2003 found that diarrhea incidence was 107.46 cases per 1,000 
population per year, while the annual incidence of shigellosis was 10.4 
per 1,000 population [4]. The disease is an alarming problem in children 
aged less than 5 years. Based on an active surveillance of this particular 
age group, the incidence rate was 64 cases per 1,000 population per 
year [5]. It is noteworthy to mention that though several international 
studies have been published on the economic aspects of enteric infections 
[6–11], no similar research has been published from Thailand. Recently, 
a health-care reform focusing on the health insurance system has 
been introduced in Thailand. Three major health insurance schemes 
operate in the country: the Social Security Scheme (SSS) for private 
employees, the Civil Servants Medical Benefit Scheme (CSMBS) for 
government servants, and the Universal Coverage of Health Care Scheme 
(UC) for the remaining two-thirds of the population. Payment methods 
for hospitals are capitation for the SSS and the UC, and fee-for-service 
for the CSMBS [12]. The newly introduced reform had an effect 
on hospital financing that resulted in unavoidable consequences to 
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patient services. To have an appropriate management of the disease in 
Thailand, there is a need to focus on the economic outcome. Hence, 
to analyze the cost of an illness is pivotal. Other than the average 
c o s t ,  c o s t  f u n c t i o n  p r o v i d e s  i n fo r m a t i o n  t h a t  m a y  h e l p  a 
decision-maker to determine whether or not a service should be 
implemented and/or reimbursed [13]. Economic information can be 
applied in both treatment and prevention. Because of the widespread 
isolation of  strains that are resistant to mult iple antibiotics, 
there are few treatment options. A vaccine to prevent illness and 
death caused by Shigella would be a valuable public health tool 
with a strong impact. There are some shigella vaccines currently 
under development with promising outcomes [1,14]. Nevertheless, 
economic evaluation is essential to include a vaccine into the vaccination 
program. Therefore, this study aims to develop a cost function 
model to estimate the public treatment cost of shigellosis patients 
in Thailand. This economic information could be useful for hospital 
management and public health planning in the future.
Methods
This study was designed as an incidence-based cost of illness study with 
a bottom-up approach [15]. Bottom-up or micro-costing approach is 
based on principles in which the actual services and then costs of 
individual patient are recorded and calculated. Costs were calculated 
from a provider perspective based on 2002 prices, and then adjusted 
to the 2006 prices using the medical care consumer price index [16]. 
The original Thai baht was converted to US$ at 38.084 baht per US$1 [17]. 
The costs in this study were economic (opportunity) costs, which are 
values of all resources used for producing services for the patients. The 
data were retrospectively collected. The study popultion was shigellosis 
patients from a surveillance project conducted on May 2002 to 
April 2003 [18]. The registered residents (39,594 males and 40,547 females) 
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of Kaengkhoi District, Saraburi Province 108 km north-east of Bangkok 
were the study population. There were 5,686 children aged less 
than 5 years and 74,455 adults [4]. Samples were collected from all 
diarrhea patients from the Kaengkhoi District who visited community 
health-care centers, the Kaengkhoi District Hospital, and the Saraburi 
Regional Hospital. These study health service facilities all belong 
to the government. Public hospitals are major health service settings in 
Thailand [19]. Rectal swap specimens were tested through the conventional 
culture method and dot-enzyme linked immunosorbent assay (Dot-ELISA) 
for shigella detection [20]. The surveillance found that the incidence of 
diarrhea among children less than 5 years was 122 cases per 1,000 population 
per year and 24.69 per 1,000 population per year among the population 
5 years and older. The incidence of diarrhea patients was 31.59, whereas 
the incidence rate of shigellosis was 1.96 per 1,000 population per year [18]. 
All shigellosis patients detected during the study period were included in 
the study. The study included in and outpatients of both genders and all 
age groups. The variables included in this study were demographic 
characteristics(sex, age, and health insurance scheme), service utilization 
(hospital services, pharmacy cost, and other medical services for diagnosis 
and treatment), and direct medical cost or public treatment cost. Treatment 
costs also included complications and sequelae for up to 90 days after 
presentation [4], but did not include costs associated with comorbidity. 
Descriptive statistics were used to summarize demographic characteristic, 
service utilization, and cost. Univariate sensitivity analysis was used 
to explore the uncertainty of the results [21]. Likewise, variations in 
discount rate, prices of drugs, and opportunity cost of land use were 
analyzed. The drug prices were the minimum and maximum prices 
reported to the Ministry of Public Health by public hospitals. The 
stepwise multiple regression analysis [22] was employed to analyze the 
relationship between the public treatment cost (dependent variable) and 
potential explanatory variables (independent  variables). Assumption and 
model diagnostics were also explored. Independent variables with a 
probability value of F statistics = 0.05 in the analysis were entered. To 
estimatethe expected response on an untransformed scale after fitting a 
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linear regression model of transformed scale, it needs to be adjusted by 
the smearing factor [23].  To retransform the predicted log of cost, 
the following equation was applied [24]. 
The public treatment cost was calculated from the provider’s perspective; 
in this case, the health facilities under the responsibility of the Ministry 
of Public Health. Saraburi Hospital has 680-bed and 1,686 staff members 
providing tertiary hospital care on a provincial/regional level. Kaengkhoi 
Hospital is a 60-bed district hospital with 146 staff members providing 
secondary hospital care for the Kaengkhoi District. Health centers are 
public health-care facilities at the sub-district level that provide primary 
health care, health promotion, and prevention (no inpatient service). 
The usual staff members include between two to six nurses and/or 
paramedics. All 19 health centers in the Kaengkhoi District participated in 
this project. The public treatment costs are defined as the direct medical 
costs at these health centers, as well as in Kaengkhoi Hospital and 
Saraburi Hospital. Cost analysis started from a calculation of the unit 
cost of the medical services of all facilities [25,26]. Unit cost analysis was 
calculated employing the same methods. The calculation consisted of 
five steps, organization analysis and cost center classification, direct cost 
determination, indirect cost determination, full cost determination, and 
calculation of unit cost of medical services [27,28]. The health service 
settings were categorized into patient care and non-patient care cost 
centers. Direct cost determination of each cost center consisted of capital, 
labor, and material costs. Capital cost consists of two components, 
[ ] 





= ∑
=
n
i
Sx ie
n
etE
1
)(
0
1)(cos β (1)
(2)= smearing factor
where eSi = antilog (exponential) form of the unstandardized residual. 
∑
=
n
i
Sie
n 1
1
t
thesis-chapter3.indd   41 4/5/2555   13:14:44
Chapter 3
42
namely capital costs of capital items and opportunity costs of land and 
stocked materials. Capital costs of buildings and capital items were 
calculated as equivalent annual economic costs [25,29]. Following 
WHO recommendations, a 3% discount rate was selected [30]. A 
lifespan of 20 years for building and constructions and 5 years for the 
rest of the capital items were used [31,32]. Labor cost includes the 
sum of salaries, wages, incentives, and fringe benefits, such as 
accommodation, training expenses, health-care expenses, and 
education expenses. Materials covered were drugs, chemicals, office 
materials,and utilities. For the hospitals, the costs of all supporting 
departments or non-patient care cost centers were allocated to 
production departments or patient care cost centers that employed 
a simultaneous allocation method [25].  Services or outputs of 
supporting cost centers were selected as allocation criteria for the 
allocation (e.g., number of staff for administration department). 
The average method [33,34] was used to calculate the unit cost of 
services of the departments producing one cost product or various 
homogeneous products in terms of resource consumption, such as 
outpatient visit, inpatient day, and drug dispensing. On the other hand, 
the micro-costing method [34,35] was used for the unit cost calculation 
of the departments that had various cost products and consumed different 
resources (e.g., laboratory, radiology, physical therapy, operating room, 
emergency room). Micro-costing is a method that allocates the cost of 
the production cost center to each unit of service. First, resources directly 
consumed by each unit of service were valued. Then, shared cost was 
allocated to the services in proportion to the direct cost of the services.
Results
The unit costs of medical services provide by Saraburi Hospital were 
higher than those of the Kaengkhoi Hospital except for some laboratory 
 investigations (Table 1). For the health centers, consultation and drug 
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dispensing were averaged to be the cost of outpatient service, which 
varied from US$1.21 to US$3.83. Some of these were higher than 
those of the Kaengkhoi Hospital. Regarding the drug cost, they were 
the hospitals’ purchasing prices. Frequently used drugs are listed in 
Table 2.
The minimum and maximum prices were the prices that the public 
hospitals reported to the Ministry of Public Health. Variations between 
the minimum and maximum prices were in the range of 1.7 (5% dextrose 
solution) to 13.7 times (norfloxacin 100 mg).
Table 1 Unit cost of some medical services (US$ at 2006 prices)
Service
Routine service: outpatient*
Routine service: female ward
Routine service: male ward
Drug dispensing for outpatient
Drug dispensing for outpatient†
Complete blood count (CBC)
Blood urea nitrogen (BUN)
Creatinine
Stool exam
Urine analysis (UA)
Occult blood
Unit
Visit
Patient day
Patient day
Prescription
Prescription
Test
Test
Test
Test
Test
Test
Unit cost
Saraburi hospital
   7.24
22.29
n/a
5.37
1.65
1.84
0.54
0.50
0.46
0.70
0.65
Kaengkhoi hospital
2.17
19.56
21.82
0.57
n/a
1.70
3.60
3.02
1.60
2.03
1.60
Health centers
   1.21 – 3.83 
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
*For Saraburi Hospital, it is a service at the emergency room. For health centers, the cost per visit is presented as a range of all health 
centers included in the study.
†For Khaengkhoi Hospital, outpatients and inpatients receive drug dispensing from the same unit.
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Table 2 Cost of drugs per 100 units (US$ at 2006 prices)
Drug
Norfloxacin 100 mg tablet
Norfloxacin 400 mg tablet
Ciprofloxacin 250 mg tablet
Domperidone tablet
Hyoscine-n-butyl bromide tablet
Metoclopramide 5 mg tablet
Paracetamol 500 mg tablet
ORS adult sachet
ORS pediatric sachet
5% Dextrose in ½ normal saline solution 1000 ml bag
Normal saline solution 1000 ml bag
Unit cost
Base-case
1.68
2.74
9.84
0.87
4.08
0.50
0.34
7.55
4.75
44.74
46.14
Minimum
0.84
1.57
2.80
0.28
1.40
0.39
0.21
2.80
2.66
41.75
38.87
Maximum
11.49
6.43
9.84
1.17
4.08
0.70
0.89
13.42
10.07
71.31
167.51
All shigella-positive cases were included. There were 137 episodes 
from 130 patients. Out of 140 outpatient visits, most patients received 
treatment at Kaengkhoi Hospital (94 visits), followed by 46 visits 
at the health centers. For the hospitalization treatment, there were 
nine and three admissions at Kaengkhoi Hospital and Saraburi 
Hospital, respectively. Nearly all patients (94.2%) received treatment 
as outpatients ( Table 3), while 6% of patients were hospitalized. 
More than half of the patients were female (63.5%). Majority of 
the patients (61.3%) were aged more than 15 years. The largest 
percentage of patients was treated at Kaengkhoi Hospital (65%). 
The antibiotics used were norfloxacin, ciprofloxaxin, cotrimoxazole, and 
tetracycline.
Patient Characteristics and Service Utilization
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Public treatment cost was defined as the sum of the cost of visit, cost 
of hospitalization, dispensing cost, drug cost, cost of medical devices, 
and laboratory cost.  The average cost per episode was US$8.65. 
Hospitalizations consumed a major part of the overall costs of 
shigellosis  treatment.  There were only 5.8% of episodes that 
received hospitalization services, but they consumed more than half 
of the total public treatment costs. This was around 59.3% of the 
total cost ( Table 4). Regarding the types of services, the routine 
service or hotel cost for inpatients consumed nearly half (46%) of 
the total cost. The routine service of outpatient and pharmacy cost 
(drug cost and drug dispensing cost) were approximately one-fourth 
(Table 4).
Public Treatment Cost
Table 3 Variables included in the regression analysis
Variable
Dependent variables LNCOST
Independent variables ADULT
Dummy variables for health providers; health 
centers (31.3%) as reference
    KH
    SR
    HCKH
Dummy variables for service type; outpatient 
(94.1%) as reference
    IP
    OPIP
Dummy variables for payment status; Universal 
Coverage Scheme (45.3%) as reference
    SSS
    CSMBS
    
   
   OOP
Codes and values
Number in Ln form of the cost
1= adult; aged more than 15 years (61.3%), 0= 
children; aged 1-15 years (38.7%)
1= Kaengkhoi Hospital, 0= else
1= Saraburi Hospital, 0= else
1= Health center and Kaengkhoi Hospital,   
     0= else
1= Inpatient service, 0= else
1= Outpatient and inpatient service, 0= else
1= Social Security Scheme, 0= else
1= Civil Servant Medical Benefit Scheme, 
     0= else
1= Self payment, 0= else
Definition and characteristics
Natural log of public treatment cost per episode
Age of patients
Kaengkhoi Hospital (65%)
Saraburi Hospital (1.5%)
Health center and Kaengkhoi Hospital (2.2%)
Inpatient (2.2%)
Outpatient and inpatient (3.6%)
Social Security Scheme (21.9%)
Civil Servant Medical Benefit Scheme (4.4%)
Out-of-Pocket (5.8%)
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Table 4  Descriptive data of public treatment costs by category of costs and services  (US$ at 2006 prices)
Cost
Cost by category
Routine service for outpatient
Routine service for inpatient
Drug dispensing cost
Drug cost
Medical devices
Laboratory
Total medical cost
Cost by service (% of sample, % of total cost)
Outpatient visit (91.3%, 37.0%)
Inpatient admission (1.5%, 10.7%)
Outpatient+inpatient*(3.6%, 41.5%)
Multivisits (2.9%, 3.7%)
Multiadmissions (0.7%, 7.1%)
Cost by age group (% of sample)
Aged less than 5 years (20.4%)
Aged 5-15 years (18.3%)
Aged more than 15 years (61.3%)
Total (100%)
Mean
2.19
4.01
0.89
1.06
0.09
0.41
8.65
3.51
63.25
98.44
10.96
84.04
6.22
9.24
9.29
8.65
(25.1%)
(46.36%)
(10.29%)
(12.27%)
(1.00%)
(4.77%)
(100%)
95% CI
Median
2.17
0.00
0.57
0.66
0.00
0.00
3.42
3.35
63.25
84.57
6.60
n/a
3.20
3.34
3.56
3.42
Lower
2.04
0.91
0.47
0.76
0.02
0.15
4.79
3.21
-433.37
30.32
-3.52
n/a
0.255
-1.63
4.09
4.79
Upper
2.34
7.11
1.31
1.37
0.15
0.68
12.51
3.81
559.87
166.57
25.43
n/a
12.19
20.10
14.50
12.51
*One visit and one admission.
Sensitivity Analysis
To explore variations of the public treatment cost of shigellosis, some cost 
drivers (i.e., cost structure, discount rate, and prices of drugs) were varied 
in repeated calculations. The base case included opportunity of land 
used and a 3% discount rate. The following scenarios were employed in 
a one-way sensitivity analysis: 
1. base case: 3% discount with cost of land use;
2. 3% discount rate for capital costing, excluding opportunity cost of 
 land used  3%NoLand);
3. 6% discount rate for capital costing, including opportunity cost of 
 land used (6%Land);
4. 6% discount rate for capital costing, excluding opportunity cost of 
 land used (6%NoLand);
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5. 3% discount rate for capital costing, including opportunity cost of 
 land used and substitution drug prices of base case by minimum prices 
 (3%LandMinPrice); and
6. 3% discount rate for capital costing, including opportunity cost of 
 land used and substitution drug prices of base case by maximum prices 
 (3%LandMaxPrice).
The total medical cost (or public treatment cost) ranged from US$8.29 
per episode (-4.20%) to US$9.38 per episode (+8.43%) because of the 
different assumptions for drug prices. (Table 5).
Public Treatment Cost Function
Potential predictor variables included in the model tested are presented 
in Table 3. Because of the non-normal distribution of institutional 
costs, a log transformation [36] was applied and a linear relationship 
among variables was tested. For further assumption tests and 
model  diagnosis,  the scattered plot  of  residuals  against  the 
predicted values and all independent variables shows no funnel 
shape indicating homoscedasticity [22]. The condition index was 
1 to 3.401.
Table 5 Results of sensitivity analysis; treatment cost per episode (US$ at 2006 prices)
Scenario
1. Base case; 3% Land
2. 3% NoLand
3. 6% Land
4. 6% NoLand
5. 3% LandMinPrice
6. 3% LandMaxPrice
Variation from base case (%)
n/a
-1.78%
4.60%
1.05%
-4.20%
8.43%
Average treatment cost
8.65
8.50
9.05
8.74
8.29
9.38
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This meets the criteria of ≤ 30; hence, indicating no multico-linearity 
[22]. The final fitted model has a determination coefficient equal to 
the adjusted R2 = 0.788, with a significance level = 0.000. The significant 
variables and regression coefficients are shown in Table 6. The smearing 
factor of the public treatment cost model was 1.0827.
Based on the fitted model, the predicted public treatment cost of a patient 
who received treatment at a health center as an outpatient and is not under 
CSMBS, is calculated as follows:
LNCOST =  0.877 + 2.970opip + 1.916ip + 0.453kh + 1.087sr  (3)
   + 0.406csmbs
LNCOST  =  0.877 + 2.970x0 + 1.916x0 + 0.453x0 + 1.087x0  (4)
   + 0.406x0 
 
LNCOST  =  0.877 (5)
Public treatment cost per episode = e0.877×1.0827  (6)
Public treatment cost per episode = US$2.60  (7)
Table 6 Regression model of public treatment cost
(Constant)
Outpatient and inpatient
Inpatient
Kaengkhoi Hospital
Saraburi Hospital
Civil Servant Medical Benefit Scheme
β
0.877
2.970
1.916
0.453
1.087
0.406
Unstandardized
coefficients
95% CI for β
t
15.075
18.043
  8.906
  6.315
  3.623
  2.388
Lower 
bound
0.762
2.644
1.491
0.311
0.493
0.070
Std. error
0.058
0.165
0.215
0.072
0.300
0.170
Sig.
0.000
0.000
0.000
0.000
0.000
0.018
Upper 
bound
0.992
3.295
2.342
0.595
1.680
0.742
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Based on the fitted model, the predicted public treatment costs of 
various scenarios were calculated as shown in Table 7.
Discussion
In view of the general results of our study, we could state that the 
results could represent most shigellosis patients in Thailand. We 
selected two types of public hospitals that represent the majority 
of public hospitals in Thailand. This is important, considering that 
public hospitals are major health service settings in Thailand. The 
patient beds of public hospitals are approximately 80% of the total beds 
in Thailand [19].
Both selected hospitals had an indication of efficient production. The 
occupancy rates of inpatient beds were nearly 100%, even as World 
Health Organization guidelines recommend conducting cost analysis at 
80% capacity utilization [30]. Another indicator of representativeness 
is resource utilization. The proportion of capital cost was 17.8% at 
Kaengkhoi Hospital and 23.47% at Saraburi Hospital, while studies in 
Table 7 Predicted public treatment cost from the fitted model (US$ at 2006 prices) 
Scenario
1
2
3
4
5
6
7
8
9
KH
no
yes
yes
no
no
yes
yes
no
no
Outpatient
yes
yes
yes
yes
yes
no
no
no
no
SH
no
no
no
yes
yes
no
no
yes
yes
Inpatient
no
no
no
no
no
yes
yes
yes
yes
CSMBS
no
no
yes
no
yes
no
yes
no
yes
HC
yes
no
no
no
no
no
no
no
no
Cost
2.60
4.10
6.15
7.72
11.58
82.52
123.80
52.44
78.68
%change*
         n/a
57%
136%
196%
345%
3070%
4656%
1915%
2923%
*% change from scenario one.
CSMBS, Civil Servant Medical Benefit Scheme; HC, Health Center; KH, Kaengkhoi Hospital; SH, Saraburi Hospital
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other hospitals were 14.73% to 15.38% in the district hospitals [37,38], 
and 15.89% to 22.21% in the regional hospitals [39,40], These are 
slightly less than those of the study hospitals because they were 
not included opportunity cost of the stocked materials. For the 
unit cost analysis, this study employed micro-costing technique 
in the allocation of cost from the cost center to the individual 
service output. This method is the most accurate [27, 41]. Nevertheless, 
the unit cost of similar medical services in varied settings can be 
different. There can be variation of unit cost estimates [41]. In this 
study, we have controlled costing methods by using the same 
methods among the study settings. In this way, variations can 
only happen as a result of the gap between the resources used 
and ser vice outputs produced. In our study, the unit costs of 
some laboratory tests at Kaengkhoi Hospital were higher than those 
of the Saraburi Hospital.  Generally, a district hospital provides 
secondary care while a regional hospital provides tertiary care. They 
have different equipments, as well as varying qualifications and 
number of staff members. Consequently, they vary in their capital 
and labor costs. In addition, they may provide a different number 
of services. In this situation, the unit costs of similar simple services 
can be different because of the unit fixed cost. Another factor that 
affects treatment cost is the prescribing pattern. We found that the 
antibiotics used in this study were similar to other studies [42]. Hence, 
the results from this study could be used in the estimation of the 
country cost.
In terms of hospital management, the information on cost structure 
is pivotal for cost management. Eight out of 137 episodes (5.8%) consumed 
a cost of 59.3% of the total treatment costs. This means that hospitalizations 
consumed a major part of the public treatment cost. Therefore, it is 
essential to control the number of admissions in order to contain 
the costs. Unfortunately, the number of inpatients was too small 
in this study to explore the factors leading to hospitalizations. 
Furthermore, the sensitivity analysis shows a considerable effect 
of drug prices on public treatment costs. Although drugs exclusive 
thesis-chapter3.indd   50 4/5/2555   13:14:45
A cost function analysis
51
of dispensing costs accounted for only 12% of the public treatment 
cost ( Table 4), drug prices affected the total cost in the range of 
-4.20% and +8.43% (Table 5). In Thailand, like in many low-income 
countries, drug prices vary considerably, and our findings may therefore 
be of wider interest. Therefore, the drug supply in hospitals is a 
target of cost containment. To know more about the details of cost 
drivers, the cost function method may be used to help provide such 
information [13]. The public treatment cost model with the adjusted 
R2 of 0.788 was statistically significant as predicted by types of 
services (outpatient and inpatient), types of providers (health center, 
district hospital, regional hospital), and health insurance scheme. This 
fitted model could be reliable because the model could explain the 
treatment cost by nearly 80%. The effect of the health service level 
on the treatment cost can also be explained. Generally, the unit costs 
per visit increased from the health centers to the district hospital 
and then to the regional  hospital .  In addit ion,  there was no 
inpatient service at the health centers. Therefore, the average total 
cost of public treatment at the health centers was less than those 
of the hospitals. Another predictor of the public treatment cost was 
the insurance scheme of patients. For example, CSMBS patients tended 
to receive drugs with higher cost (they take brand name drugs 
instead of generic drugs) and longer hospitalization. The CSMBS 
is a fee-for-service payment scheme, while the other insurance 
schemes are capitation schemes. This results to a scenario of unequal 
treatments among patients with different payment schemes. This 
is related to the issue of equity in health and needs to be further 
investigated. 
Based on the stepwise method that was used, we concluded that 
there is no difference in the treatment cost between adults and 
children. Because admission is a significant factor, we tested and 
found that there is no statistically significant difference in the rates 
of admission between adults and children (Fisher ’s exact test; 
P = 0.297). Another factor that might have affected the difference 
in the public treatment costs of adults and children was drug cost. 
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Nevertheless, Table 4 shows that drugs exclusive of dispensing costs 
accounted for only 12% of the public treatment cost. This proportion 
might not be big enough to affect the public treatment cost. Various 
scenarios according to service types, providers, and health insurance 
schemes show high variations in cost. As shown in Table 7, for the 
same condition, patients treated at health centers were able to save 
as much as US$1.5 per episode in comparison with those treated at 
the district hospital (scenario 1 versus 2 in Table 7). The treatment cost 
increased to 2,923% from that of the health center. The treatment 
cost function is useful because it provides an estimated quantity of 
cost difference among the various scenarios. In the future, this 
would be applicable in feasibility studies on health interventions. 
Never theless,  the consequences for  the qual ity of  treatment 
should be further investigated.
Based on the results of this study and the overall incidence of 
shigellosis in 10.4 per 1,000 population per year [4], the annual 
cost because of shigellosis in Thailand is estimated at US$5.60 
million. Bearing this in mind, the priority setting of the country’s 
public health planning could be affected. Furthermore, costing studies 
can be applied to the design of interventions. Generally, the cost 
and outcome of interventions should be estimated during planning. 
The economic outcome is  one of  the most impor tant factors 
to take into consideration. Cost-benefit is an alternative evaluation 
method. The number of illness that could be avoided with information 
on the cost of illness can be used in the calculation of savings to 
compare the intervention cost. In the same district where this 
study was conducted, another study was done on the risk factors 
of shigellosis. This particular study showed that hygiene behaviors such 
as regular hand washing, a clean household and environment, and the 
availability of water to flush the toilet were associated with a reduced 
risk for shigellosis in the multivariate model [43]. If an intervention 
such as hand washing is targeted to reduce shigellosis by 10%, this 
can produce a savings of US$0.56 million. In terms of the project design, 
the cost of the intervention should not be higher than the amount of the 
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expected savings.
Another interesting intervention is vaccination. The information from 
our studies and others similar to it could be useful for vaccine 
development. The success of vaccination does not solely depend 
on the development of a vaccine, but also on its wide coverage. 
One of the factors that affect vaccination compliance is affordability. 
I f  we have information on an affordable pr ice,  i t  could have 
an effect on the development of a production technique that relates 
to the targeted prices. Currently, there are some shigellosis vaccines 
under development [1, 14]. Information on treatment cost from 
this study and previous epidemiological studies, including further 
estimation of vaccine delivery cost, can be used in a modeling 
design of  cost-effectiveness analysis (CEA) [44] for a shigella vaccine. 
The analysis can be per formed for all  age groups or high-risk 
groups whose age are less than 5 years old [5]. The fitted model 
provided an estimated cost of treatment at various settings. This 
can be useful for a CEA in a specific geographic area. For example, 
we may implement the vaccination only in a high-incidence area. 
This area may have a different proportion of treatment among 
health center and the hospital. Based on the costs between the 
health center and the hospital, as shown in Table 7, we can calculate 
the weighted average treatment cost in that area for the CEA. 
In addition, the threshold analysis [45,46] method may be used to show 
the break-even price of the vaccine. This price can be one of the targets 
for vaccine development.
Conclusion
The average public treatment cost of shigellosis in Thailand was 
determined to be US$8.65 per episode. Approximately 6% of these 
episodes consumed 60% of the total cost. Service types, health-care 
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facilities, and insurance schemes were predictors of nearly 80% 
of the cost. The estimated cost can be employed for hospital management 
and health problem priority setting and planning. The fitted cost 
model was useful in estimating the treatment cost of various scenarios. 
These estimated costs can be applied in a feasibility study of health 
interventions. Furthermore, it can be useful information for vaccine 
development.
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Introduction:   Although a sizeable budget is available for HIV/AIDS control 
in Thailand, there will never be enough resources to implement every 
programme for all target groups at full scale. As such, there is a need to 
prioritise HIV/AIDS programmes. However, as of yet, there is no evidence 
on the criteria that should guide the priority setting of HIV/AIDS programmes 
in Thailand, including their relative importance. Also, it is not clear whether 
different stakeholders share similar preferences.
Methods: Criteria for priority setting of HIV/AIDS interventions in Thailand 
were identified in group discussions with policy makers, people living 
with HIV/AIDS (PLWHA), and community members (i.e. village health 
volunteers (VHVs)). On the basis of these, discrete choice experiments 
were designed and administered among 28 policy makers, 74 PLWHA, 
and 50 VHVs. 
Results: In order of importance, policy makers expressed a preference 
for interventions that are highly effective, that are preventive of nature 
(as compared to care and treatment), that are based on strong scientific 
evidence, that target high risk groups (as compared to teenagers, adults, or 
children), and that target both genders (rather than only men or women). 
PLWHA and VHVs had similar preferences but the former group expressed 
a strong preference for care and treatment for AIDS patients. 
Conclusions: The study has identified criteria for priority setting of HIV/AIDS 
interventions in Thailand, and revealed that different stakeholders have 
different preferences vis-à-vis these criteria. This could be used for a broad 
ranking of interventions, and as such as a basis for more detailed priority 
setting, taking into account also qualitative criteria.
Abstract 
priority setting, discrete choice experiment, HIV/AIDS interventions
Keywords
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While the number of new HIV positive cases in Thailand decreases [1-3], 
HIV/AIDS continues to take a large toll in the country with 610,000 
prevalent cases and approximately 30,000 deaths in 2007 [2]. A wide 
array of HIV/AIDS control programmes has been implemented to 
confront the epidemic since the first wave of infections in the mid-1980s 
[1, 4]. Thailand’s current national plan for HIV/AIDS prevention and 
alleviation, 2007–2011 [3] aims to: (i) integrate AIDS prevention, care, 
treatment, and impact reduction implementation into service provision 
at all levels; (ii) strengthen community’s education about AIDS; (iii) 
enhance capacity of local administration in taking responsibility on 
local HIV/AIDS interventions; and (iv) prevent HIV transmission among 
children in schools and high-risk population groups. To date, the Thai 
government provides universal coverage for antiretroviral medication 
to all eligible people living with HIV/AIDS (PLWHA) [5]. However, HIV- 
related absenteeism and the need of informal care (e.g. care givers) have 
notable effects on individual PLWHA’s economic burden [6].
Although a sizeable budget for implementation of this plan is available - 
approximately US$193 million in 2008 derived from both the Thai 
government and the International Monetary Fund [3] - there will never be 
enough resources to implement every programme for all target groups at full 
scale. As such, there is a need to prioritise HIV/AIDS programmes within the 
available budget, and to decide on which programmes will receive 
funding and which programmes will not. 
A number of criteria can guide this priority setting process [7]. First, 
cost-effectiveness, or efficiency, aims to maximize population health 
given a certain budget. A limited number of cost-effectiveness analyses 
have been performed in Thailand [8], including (i) routine offer of HIV 
counseling and testing [9]; (ii) donated blood screening by nucleic acid 
testing [10]; (iii) HIV vaccination [11], and (iv) the prevention programme 
of mother-to-child transmission of HIV [12]. Secondly, equity or fairness, 
aims to minimize differences in health among population groups, with 
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special reference to the severely ill, disadvantaged, or vulnerable popula-
tions [13]. Thirdly, the Thai government may hold preferences to target 
specific population groups, because they are more deserving of health 
care than others. The HIV/AIDS epidemics in Thailand concerns various 
population groups, including high-risk groups such as male homosexuals, 
intravenous drug users, and low-risk groups as the general population 
 including teenagers, adults, and elderly [4, 14]. In addition, a wide 
range of other medical (e.g. preference for acute care in life threatening 
situation) and non-medical criteria (e.g. preferences for programmes with 
desirable social consequences) may play a role in priority setting process 
[7, 14-17]. 
It is clear that relying on a single criterion, e.g. efficiency, falls short to 
capture the important moral and ethical notions, and is unlikely to be 
acceptable for most policy makers [18-21] including those in Thailand 
[22]. The challenge for policy makers in Thailand is then to find the 
right balance between the various criteria. The trade-off a country like 
Thailand makes between e.g. efficiency and equity criteria can have 
important implications, e.g. adopting severity of disease rather than cost-
effectiveness as guiding principle in the selection of HIV/AIDS interventions 
– and thus choosing treatment rather than prevention-centered strategies 
– could lead to a large number of extra infections in Thailand [14]. 
However, as of yet, there is no evidence on the criteria that should guide 
the priority setting of HIV/AIDS programmes in Thailand, including their 
relative importance. Also, it is not clear whether different stakeholders 
share similar preferences. It is against this background that this paper 
elicits preferences on the relative importance of criteria for priority setting 
of HIV/AIDS programmes in Thailand from policy makers, PLWHA and 
community members. The study uses discrete choice experiments (DCE) 
to elicit explicit preferences in HIV/AIDS area, and is the first study 
to do so in this area. The technique allows the assessment of the 
relative importance of different criteria that influence choice, in this 
case the priority setting of health interventions in HIV/AIDS control. 
The technique has shown promising results in a number of other 
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disease areas in low-income settings [23-25]. The present study can 
hence be interpreted as exploratory, to test the feasibility of the 
approach, and have a first impression of its findings.
Discrete choice experiments
Discrete choice experiments are a quantitative methodology for 
evaluating the relative importance of the different product attributes 
that influence consumer choice behavior [26]. In such experiments, 
respondents are asked to make choices between hypothetical alternative 
goods or services. 
We employed DCE to determine the relative importance of criteria 
for priority setting, according to various stakeholders. In a DCE, 
respondents choose their preferred option from sets of hypothetical 
scenarios, each consisting of a bundle of criteria that describe the 
scenario in question. The criteria are constant in each scenario, but the 
levels that describe each criterion may vary across scenarios. Analysis 
of the options chosen by respondents in each scenario reveals the 
extent to which each criterion is important to the decision at hand [27, 28]. 
Running a DCE involves selection of participants, identification of criteria 
through group discussion, DCE design and administration of the DCE survey. 
These are discussed in turn.
Participants
In this study, we chose to explore the views of policy makers in comparison 
with two other groups of stakeholders, i.e. PLWHA, and community 
members represented by village health volunteers (VHVs). 
The policy makers were represented by 28 national – and province level 
decision makers strongly involved in health resource allocation 
decisions in Thailand specifically on HIV/AIDS. As a first step in the 
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selection process, members of the National AIDS Committee were 
asked to participate. As a second step, they were asked to nominate 
other decision-makers meeting the above criterion. A total of 
30 decision makers were invited, and 28 agreed to participate in 
the study. They were predominantly male (71.4%), and all being higher 
educated (bachelor degree or more) (Table 1).
The PLWHA were all members of the Thai network for people living with 
HIV/AIDS, representing PLWHA groups at the province and regional 
level in Thailand.  In a regular network-meeting, we invited the members 
to participate in the present study.  In total, 74 out of 85 invited PLWHA 
agreed to participate. They were predominantly female (61%) with a minority 
being higher educated. 
The community members were represented by VHVs – these are 
community members who have been trained by public health providers 
Table 1   General characteristics of respondents
Age  (years)
   mean (SD)
Gender
   male
   female
   missing
Education
   lower than bachelor
   bachelor degree
   master degree
   doctoral degree
   missing
Occupation
   government officer
   private company employee
   agriculturists
   housewives
   freelancers/self-employee
   others
   missing
47.4  (6.9)
 
20 (71.4%)
8 (28.6%)
- 
 
- 
4 (14.8%)
16 (59.3%)
7 (25.9%)
1 
 
27 (100.0%)
- 
- 
- 
- 
- 
1
 
 
33.1 (5.5)
 
28 (38.9%)
44 (61.1%)
2 
 
44 (61.1%)
27 (37.5%)
1 (1.4%)
- 
2 
 
1 (1.4%)
4 (5.6%)
5 (7.0%)
- 
54 (76%)
7 (9.8%)
3
 
47.6  (9.0)
 
6 (12.0%)
44 (88.0%)
- 
 
40 (80.0%)
10 (20.0%)
- 
- 
- 
 
4 (8.0%)
3 (6.0%)
2 (4.0%)
30 (60.0%)
3 (6.0%)
8 (16.0%)
-
 
Perspective
Village Health Volunteers
(n = 50)
People living with HIV/AIDS
(n =74)
Policy makers
(n = 28)
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in order to provide basic health care delivery including first aid and 
necessary health information to members of the village they reside in. 
In the selection process, we invited 100 VHVs in a semi-urban district of 
Samutprakan province, and out of these, 50 agreed to participate. They 
were predominantly female (80%), with a minority being higher educated.
Table 2   Attributes and levels
Attributes 
Target group
Gender of 
target group
Type of intervention
Effectiveness
Quality of evidence  
on effectiveness
Levels
Children (Child)
Teenagers
High risk adults
All adults
Male
Female
Both genders
Treatment and care of patients with HIV 
(not AIDS)
Treatment and care of patients with AIDS
Preventing HIV
Low effective
High effective
Weak evidence
Strong evidence
Level coding
Child
Teen
HiRisk
Adults
Male
Female
BothGen
HIV
AIDS
Prevent
LoEff
HiEff
Weak
Strong
Definition
0 - 12 years old
13 - 20 years old
≥ 21 years old with high risk behavior e.g. sex work-
ers, men who have sex with men, injected drug 
users, pregnant women, etc.
≥ 21 years old without any specification
aiming to male population
aiming to female population
not specify gender of target group
aiming to treat HIV infected people (CD4 ≥ 200) and 
reduce HIV transmission
aiming to treat AIDS patients (CD4 < 200)
aiming to prevent general publics from HIV 
infection
less than 50% of participants benefit
more than 50% of participants benefit
no evidence but observation and/or expert 
opinions 
evidence from domestic and/or international 
literatures
Identification of criteria and criteria levels
To define the criteria in DCE, group discussions were organized with 
each group of stakeholders including six representatives of that group. 
As an initial step, two HIV/AIDS interventions were presented. Then 
participants were asked to decide which intervention should be 
funded and reasons for the choices were discussed. The discussion 
was then broadened to discuss general reasons, or criteria, to fund 
HIV/AIDS interventions, and finally agreement was reached on a 
comprehensive set of criteria. Resulting criteria and associated levels 
from the three group discussions were compared. The final selection 
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of criteria and levels included those that were identified by two or more 
discussion groups. This resulted in identification of one criterion at four 
levels, two criteria at three levels, and two criteria at two levels (Table 2).
DCE design
The DCE was designed on the following principles. To avoid information 
overload from a full factorial of 144 possible scenarios based on 
identified criteria and levels (41×32×22), a limited number is chosen 
on the basis of a fractional experimental designs catalogue produced 
by Hahn and Shapiro [29]. The catalogue includes a number of 
orthogonal designs, both full factorial and fractional factorial ones, 
with differing numbers of attributes at differing numbers of levels. 
The fractional factorial design – fitting the number of identified criteria 
and levels – included a subset of 16 scenarios (representing an orthogonal 
array and minimizing multicollinearity), to allow the estimation of all 
main effects. Each of these 16 scenarios was paired by fold-over technique. 
A two-scenario with non-labeled experimental design was employed 
for each choice set. The plausibility of each scenario was evaluated with 
experts, policy makers, and in a pilot study with VHVs. An example 
of scenario for this DCE is presented in Table 3.
DCE survey
The DCE survey was administrated to policy makers through face-
to-face interview and to the other groups by self-administered 
questionnaires. For the latter groups, group meetings were organized 
to clarify the aims of the DCE survey and the questionnaire. At completion 
of the questionnaire, participants were asked to simply rank order 
the criteria included in the DCE on the basis of their importance 
in priority setting of HIV/AIDS interventions. To standardize and 
maintain quality of the data collection, the group discussion and 
interviews were conducted only by the first author.
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Data analysis
Regression coefficients, average marginal effects, and relative contributions 
were estimated from the response data by the statistical software program 
STATA 10.0. Regression coefficients indicate the sign of the effect of a variable 
on the probability of selection of an intervention. Since the response 
data is a dichotomous outcome – ‘1’ is coded for being chosen, with ‘0’ is 
coded for not being chosen – and dummy coding was used to transform 
the attribute levels into L-1 dummy variables in which each dummy is set 
equal to 1 when the qualitative level is present and set equal to 0 if it is not. 
Binary logistic regression models were used to analyze the data, with the 
following description,
Logit(P)  =  β0 + β1-3 Target group + β4-5 Gender of target group + 
  β6-7 Type of intervention + β8 Effectiveness +         (1)
  β9 Quality of evidence on effectiveness + ε   
Table 3   Example of DCE question and explanatory note
Choice set 1 
Target group
Gender of target group
Type of intervention
Effectiveness
Quality of evidence on effectiveness 
Which one would you choose? Please 
tick a box
Imagine that you were a Thai health policy maker faced with priority setting decisions on how to allocate scarce budgets. Given that 
only one of the two options below can receive funding, which one would you choose?
Explanatory note
Option A An intervention aims to prevent people who are ≥21 years of age with high risk behavior e.g. female sex workers, injecting 
 drug users, and gay men from HIV infection. There is evidence from domestic or international literature presenting that 
 less than 50% of participants in this intervention can protect themselves from HIV infection. 
Option B An intervention aims to treat HIV infected female who are ≥21 years of age. There is no evidence to support the effectiveness 
 of this intervention; however, experts believe that more than 50% of participants can be treated or can reduce HIV 
 transmission. 
A
high risk adults
both genders
preventing HIV
low effective
strong evidence
B
all adults
female
treatment & care of patients with HIV
high effective
weak evidence
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where P is the probability of an intervention being selected by the 
respondents, β0 is the constant term, βi (i=1-9) are the coefficients 
of the model indicating the probability of selection relative to the 
reference criterion level, and ε is the unobservable error term. To control 
for differences in attractiveness of DCE scenarios, dummies were added 
for scenarios to equation (1). 
Marginal effects reflect the change in the probability of selection of an 
intervention. These were computed by taking the average difference 
in predicted probability of P with and without the variable, while 
holding the distribution of the other variables at their sample value, 
and then taking the sample mean of these differences.
The relative contributions were calculated to signify the contribution 
of one criterion to the variation in preferences explained by the 
regression model and therefore describe the relative importance of 
the various criteria in the choice of interventions. This relative importance 
depends on the variation in the levels that are chosen for each of the 
attributes. Variation explained by the model is based on Efron's R2 [30],
 
                             
         (2)
where yi indicates the observed choice and πi indicates the predicted 
probability that choice equal to 1. The relative contributions are 
calculated by computing Efron’s R2 of the above model minus Efron’s 
R2 of the model where the criterion is held constant at its sample mean. 
This procedure shows the contribution of criteria irrespective of the 
number of levels they have.
To test whether the decision makings on choice selections vary between 
perspectives, the likelihood ratio test was analyzed. At the end, as 
a validity check, the resulting rank ordering of attributes derived from 
DCE exercise was compared (presented by the relative contributions) to 
R2          = 1 -Efron
∑i(yi - πi)2
∑i(yi - yi)2
^
^
_
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those derived from a simple rank ordering. 
Research ethics
This study was approved by Institute for the Development of Human 
Research Protections (IHRP), Ministry of Public Health, Thailand. All 
participants provided their written informed consent for the discussion 
and the interview.
Table 4 shows the results of logistic regression analysis and marginal 
effects calculation from the DCE response data, for each group of 
stakeholders. First, policy makers expressed a preference for highly 
effective interventions compared to those with low effectiveness, 
as indicated by the marginal effects. These show that the former 
interventions have a 38.5% higher probability of being selected 
than the latter. The next important criterion is intervention type, 
and policy makers expressed a preference for preventive interventions, 
followed by treatment of and care for HIV-infected people, and treatment 
of and care for AIDS-patients. The marginal effects show that preventive 
interventions have a 33% higher probability to be selected than 
the latter. Next, policy makers expressed a preference for interventions 
with strong evidence on intervention effectiveness compared to 
weak evidence.  Also,  pol ic y  makers  preferred inter vent ions 
that target high risk groups, followed by teenagers, adults, and 
children. Policy makers revealed a weak preference for gender of 
target group, with a priority to target both genders, followed by 
males and then females. 
Second, PLWHA had similar preferences as policy makers with some 
exceptions. Most notably, PLWHA expressed a strong preference for 
treatment or care for AIDS patients, and the probability of selection of 
these interventions is 24.5% higher than treatment and care for HIV- 
Results
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infectious people. Moreover, they expressed a strong preference for targeting 
both genders rather than one gender only. Third, VHVs preferences cohered 
largely with that of policy makers. 
The different models for policy makers, PLWHA and VHVs demonstrate 
a good fit as indicated by the pseudo R2, and Hosmer-Lemeshow chi- 
square. The likelihood ratio test presents that the preferences on the criteria 
of each group of stakeholders are significantly different.
Table 4   Discrete choice model results and marginal effects by perspective
Criteria
Target group
Gender of 
target 
group
Type of 
intervention
Effectiveness
Quality of 
evidence
on 
effectiveness
Levels
Child
Teen
HiRrisk
Adults
Male
Female
BothGen
HIV
AIDS
Prevent
LoEff
HiEff
Weak
Strong
Coefficient
(95% CI)
 
1.049*
(0.445, 1.654)
1.153*
(0.502, 1.803)
0.023
(-0.470, 0.517)
 
-0.256
(-0.762, 0.250)
0.266
(-0.131, 0.663)
 
-0.493*
(-0.904, -0.081) 
1.967*
(1.450, 2.485)
 
1.983*
(1.643, 2.323)
 
1.310*
(0.976, 1.645)
Coefficient
(95% CI)
   
0.135
(-0.169, 0.440)
0.022
(-0.323, 0.368)
-0.279
(-0.575, 0.017)
   
0.082
(-0.184, 0.348)
1.132*
(0.911, 1.354)
   
1.091*
(0.869, 1.313)
0.212
(-0.052, 0.476)
   
0.627*
(0.54, 0.800)
   
0.356*
(0.183, 0.528)
Coefficient 
(95% CI)
 
0.830*
(0.464, 1.196)
0.314
(-0.105, 0.734)
-0.249
(-0.609, 0.112)
   
0.196
(-0.123, 0.514)
0.724*
(0.458, 0.990)
   
-0.476*
(-0.744, -0.208)
0.246
(-0.078, 0.569)
   
1.185*
(0.973, 1.395)
   
0.349*
(0.139, 0.560)
Marginal 
effect
 
0.183
0.199
0.004
 
-0.043
0.045
 
-0.088
0.333
 
0.385
 
0.237
Marginal 
effect
 
0.030
0.005
-0.061
 
0.018
0.255
 
0.245
0.047
 
0.140
 
0.079
Marginal 
effect
 
0.181
0.069
-0.054
 
0.043
0.161
 
-0.105
0.054
 
0.275
 
0.077
(p-value)
 
(0.001)
(0.001)
(0.926)
 
(0.321)
(0.189)
 
(0.019)
(0.000)
(0.000)
 
(0.000)
(p-value)
 
(0.385)
(0.900)
(0.065)
 
(0.544)
(0.000)
 
(0.000)
(0.116)
(0.000)
(0.000)
(p-value)
 
(0.000)
(0.142)
(0.176)
 
(0.229)
(0.000)
(0.001)
(0.137)
 
(0.000)
 
(0.001)
Perspectives
Policy makers
-424.4532
0.2747
1.36
(0.995)
Log likelihood
Pseudo R2
Hosmer-Lemeshow chi-square
(p-value)
People living with HIV/AIDS
-1434.3323
0.0992
2.79
(0.947)
Village Health Volunteers
-963.3818
0.0984
1.87
(0.985)
*Significant variables (p < 0.05), Likelihood ratio test (p<0.000)
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The contribution R2 indicates the overall importance of criteria 
(Table 5). Policy makers considered intervention effectiveness as the 
most important criterion, followed by intervention type, quality of 
evidence, target group, and gender of target group. PLWHA considered 
gender of target group as most important criterion, followed by 
intervention type, intervention effectiveness, quality of evidence, 
and target group. VHVs considered intervention effectiveness as 
most important, followed by target group, gender of target group, type 
of intervention, and quality of evidence. Table 5 also shows the results of 
the simple rank ordering of criteria, and it reveals large overlaps for the 
policy makers, but less so for PLWHA and VHVs.
DCE, discrete choice experiments; R2, contribution R2
Table 5 Rank ordering of criteria in simple ranking and DCE exercise
Simple ranking
   
   Rank 1
   Rank 2
   Rank 3
   Rank 4
   Rank 5
DCE 
   
   Rank 1
   Rank 2
   Rank 3
   Rank 4
   Rank 5
 Perspective
Policy makers
  
Effectiveness 
Target group 
Type of intervention 
Quality of evidence 
Gender of target group 
 R2
Effectiveness 0.152
Type of intervention 0.091
Quality of evidence 0.053
Target group 0.015
Gender of target group 0.014
People living with HIV/AIDS
  
 Target group 
 Effectiveness 
 Quality of evidence 
 Type of intervention 
 Gender of target group 
  
 R2
Gender of target group 0.058
Type of intervention 0.042
Effectiveness 0.019
Quality of evidence 0.008
Target group 0.003
Village Health Volunteers
  
Target group 
Gender of target group 
Type of intervention 
Effectiveness 
Quality of evidence 
  
 R2
Effectiveness  0.075
Target group  0.017
Gender of target group 0.016
Type of intervention 0.013
Quality of evidence 0.006
The study has identified criteria for priority setting of HIV/AIDS  interventions 
in Thailand using perspective of policy makers, PLWHA, and VHVs, 
and revealed that different stakeholders have different preferences 
Discussion
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vis-à-vis these criteria. A number of observations can be made. 
First, the findings show that policy makers give priority to preventing 
HIV interventions, and targeting high risk populations. This is in line 
with the Thai national policy on priority setting of HIV interventions, 
which focuses on prevention among people who may be the most 
at risk of transmitting HIV [3]. Yet, although policy makers may put 
higher priority on HIV prevention programs, it is obvious that therapy 
cannot be neglected [3, 14, 19]. The Thai national HIV/AIDS plan emphasizes 
integrating HIV and AIDS prevention and treatment programs [3, 31]. 
The emphasis on intervention effectiveness and related quality 
of evidence confirms the importance that is attributed to evidence-based 
 medicine in Thailand [8].  
Secondly, the study reveals large similarities in the preferences 
for criteria for HIV/AIDS interventions between policy makers and 
VHVs. This may indicate that the preferences of community members 
(based on the sample used) are well reflected through decisions 
made by policy makers. This study also highlights the differences 
in preferences between PLWHA and the other stakeholder groups. 
The preferences of the former for care and treatment may reflect 
self-interests, whereas the preferences of the latter may reflect 
preferences for the society at large. 
Thirdly, our findings show overlap between the ranking of criteria resulting 
from DCE and as obtained from simple ranking for policy makers, but less 
so for other stakeholders. This may indicate validity and hence usefulness 
of DCE for (well-educated) policy makers, but possibly less so for other (less-
educated) stakeholders.
Recently, a number of empirical priority setting studies have included 
the views of different stakeholders, such as patients and community 
members, besides those of policy makers [32]. Inclusion of different 
perspectives is important, to enhance the legitimacy of the priority 
setting process, as has been acknowledged in the Accountability for 
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Reasonableness framework [33]. The present study is a first step to 
integrate different views, by documenting differences and similarities. 
The study did not aim to reach consensus by the different stakeholders, 
and it is not sure which methodology could be used to accommodate this. 
A challenge here is to avoid dominance by one group stakeholder (e.g. 
policy makers) over another (e.g. community members).
The DCE in this study only includes the criteria that were found to 
overlap from the focus group discussions. The rationale for doing so 
was to accommodate comparability of study findings (so to include 
identical criteria in DCE for the various stakeholders) on the one hand, 
while maintaining the number of criteria to a manageable number 
(thus not including all possible criteria that were put forward by 
any discussion group) on the other hand. However, this choice may 
have led to the omission of important criteria for some groups of 
stakeholders, and may have reduced the validity of study findings. 
Next studies should seek to strike a balance between comparability 
and validity. 
Our study findings are based on small sample sizes (ranging from 28 for 
policy makers, to 74 for PLWHA), and should therefore be interpreted with 
caution. This also indicates the explorative character of our study. A proper 
sample size calculation is difficult in the absence a prior information on 
the variances on the responses -  we based our sample sizes on previous 
similar studies, e.g. in Ghana [23] and Nepal [24] that also included a limited 
number of respondents. 
Intervention utility can be calculated by assuming a main effects 
additive utility model on the basis of a linear combination of the 
weights of each level of all criteria [28]. This utility can then be 
compared to costs, to derivate a cost-utility estimate. Subsequently, 
interventions can then be rank ordered on the basis of these cost-utility 
estimates, and this rank ordering reflects the overall intervention 
attractiveness. A rank ordering of HIV/AIDS interventions on the basis 
of cost-utility information can be used to inform policy decision making, 
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and is topic for further research. This is conceptually more consistent 
approach than considering cost-effectiveness as a separate criterion, 
as applied in other similar studies [23, 25]. However, cost-effectiveness as 
a separate criterion also has much appeal to policy makers, and is 
not clear which approach is best in supporting decision in real-life. 
  
The present study findings, and associated rank ordering of HIV/AIDS 
interventions, can be considered as general principles to prioritisation 
of HIV/AIDS interventions in Thailand. Since the DCE design only involves 
a set of criteria amendable to quantification, it ignores a range of non-
quantifiable considerations – e.g. ethical, political, and social concerns [34, 
35].  As such, any rank ordering of intervention can be indicative only, and 
should never be interpreted in a mathematical manner. In this respect, 
a broad clustering or typology of interventions that are probable ‘good 
candidates for implementation’, ‘not good candidates for implementation’, 
and ‘in-between’ is perhaps a good way to present results to policy 
makers. Such a broad typology is then a starting point for a more detailed 
priority setting process, in which policy makers can still deviate from the 
broad recommendations. A deliberative process is able to include the 
non-quantitative criteria and can encourage participatory approaches 
with a variety of stakeholders and interests [36, 37]. 
This exploratory study has shown the feasibility of eliciting explicit 
preferences on the criteria for prioritisation of HIV/AIDS interventions 
in Thailand. Further studies should refine methodological aspects, 
and interpret the findings in terms of the prioritisation of interventions.  
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Introduction:   A wide range of preventive, treatment, and care programmes for 
HIV/AIDS are currently available and some of them have been implemented 
in Thailand. Policy makers are now facing challenges on how the scarce 
resources for HIV/AIDS control can be spent more wisely. Although 
effectiveness and cost-effectiveness information is useful for guiding policy 
decisions, empirical evidence indicates the importance of other criteria, 
such as equity and the characteristics of the target population, also play 
important roles in priority setting. This study aims to experiment with the 
use of multi-criteria decision analysis (MCDA) to prioritise interventions in 
HIV/AIDS control in Thailand.
Methods: We used MCDA to rank order 40 HIV/AIDS interventions on the 
basis of priority setting criteria put forward by three groups of stakeholders 
including policy makers, people living with HIV/AIDs (PLWHA), and village 
health volunteers (VHVs). MCDA incorporated an explicit component of 
deliberation to let stakeholders reflect on the rank ordering, and adapt 
where necessary. 
Results: Upon deliberation, policy makers expressed a preference for 
programmes that target high risk groups such as men who have sex with 
men, injecting drug users and female sex workers. The VHVs preferred 
interventions that target the youth or the general population, and 
gave lower priority to programmes that target high risk groups. PLWHA gave 
all interventions the same priority. The rank order correlation between 
the priorities as expressed before and after deliberation was 37% among 
the policy makers and 46% among the VHVs.
Conclusions: This study documented the feasibility of MCDA to prioritise 
HIV/AIDS interventions in Thailand, and has shown the usefulness of 
deliberative process as an integrated component of MCDA. MCDA holds 
potential to contribute to a more transparent and accountable 
priority setting process, and further application of this approach in 
the prioritisation of health interventions is warranted.
Abstract 
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Since HIV/AIDS has long been recognized as a leading cause of death and 
a high burden of disease in Thailand [1-3], a wide range of preventive, 
treatment and care programmes have been implemented to combat 
the disease. Recently, it was suggested that funding decisions on these 
programmes are not taken in a systematic manner and that the resulting 
mix of interventions is not offering the best value for money [4]. 
Consequently, Thai policy makers now face the challenge on how scarce 
resources available for HIV/AIDS control can be spent more wisely. 
A range of studies are available to guide Thai policy makers to prioritise 
HIV/AIDS interventions. International estimates are available on the 
effectiveness and cost-effectiveness of HIV/AIDS interventions [5-7], 
and a recent document has systematically reviewed this information - in 
combination with national estimates - to provide informed priorities for 
HIV/AIDS control [4]. Yet the analysis falls short of including other criteria 
that may also play important roles in effective decision-making, such 
as ethical and social concerns. For example, the preference of society 
 to pursue not only efficiency goals (that could result in prevention-oriented 
strategies for the general population) but also equity goals (that could, for 
example, result in treatment-oriented strategies for the severely ill) may have 
a large impact on the choice of programmes [8-10]. This indicates the need 
for multiple criteria decision analysis (MCDA) to account for other criteria 
beyond effectiveness and cost-effectiveness in decision-making process 
[11-14]. 
Although MCDA is used in only a few applications to guide the making 
of resource allocation decisions on health, it is routinely used in 
environmental, agricultural and marketing sciences to set intervention 
priorities [14]. In those disciplines, MCDA has evolved as a response to 
the observed inability of people to effectively analyse multiple streams 
of dissimilar information. The analysis establishes preferences between 
interventions by reference to an explicit set of criteria that the decision-
making body has identified. A key component of every MCDA is the 
Introduction
thesis-chapter5.indd   82 4/5/2555   13:16:35
MCDA for setting priorities on HIV/AIDS
83
The MCDA in the present study includes three components. Firstly, we 
assessed the performance of interventions on the criteria as identified 
in the DCE (i.e. we constructed the performance matrix). Second, we ranked 
ordered interventions. Third, we engaged with the various stakeholders 
Methods
performance matrix that describes the performance of the interventions 
against each criterion. The performance matrix may be the final product of 
the analysis, allowing the decision makers to qualitatively rank the 
interventions. Such intuitive processing of the data can be quick and 
effective, but it may also lead to the use of unjustified assumptions, causing 
an incorrect ranking of options. In analytically more sophisticated 
MCDA techniques, the information in the basic matrix is usually converted 
into consistent numerical values. The key idea is to construct scales representing 
preferences for the consequences, to weigh the scales for their relative 
impor tance,  and then to calculate weighted averages across 
the preference scales [14]. In recent applications of MCDA [15-19], it has 
been criticised for its quantitative nature – studies typically rank 
ordered interventions on the basis of weighted averages, and in 
this way, consider quantifiable criteria only. To date, some attempts 
to capture non-quantifiable criteria to support the deliberative 
process have been reported [20,21]. This confirms that MCDA should 
rather include a deliberative process or other qualitative tools to also 
consider non-quantifiable concerns [20,22-25] and foster well-balanced 
judgments on intervention priorities [26,27]. 
The primary aim of this study is to experiment with the use of MCDA, 
including the use of deliberative process to prioritise interventions 
in HIV/AIDS control in Thailand. This research follows up on a recent 
study that employed discrete choice experiments (DCE) to identify 
and measure the relative importance of various quantifiable and 
non-quantifiable criteria for priority setting of HIV/AIDS interventions 
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in a deliberative process to adapt the rank ordering where necessary. We 
also compared the rank order of interventions before and after the delibera-
tive process. These components are discussed in turn. 
Constructing the performance matrix
As a starting point, we identified a broad set of 40 HIV/AIDS interventions 
that are implemented, or eligible for implementation, in Thailand. We then 
constructed the performance matrix, i.e. we scored each of the selected HIV/
AIDS interventions as a function of their performance on a set of criteria 
as identified in a recent DCE study [28]. This study identified the criteria 
to be relevant to the priority setting of HIV/AIDS control in Thailand 
through group discussions with each group of stakeholders including 
policy makers, people living with HIV/AIDS (PLWHA), and community 
members represented by village health volunteers (VHVs). The resulting 
criteria from the three group discussions were compared and finally 
those that were identified by two or more discussion groups were 
selected. These included: target groups of interventions (i.e. children, 
teenagers, adults, and high-risk adults); gender of target groups (i.e. 
female versus male); type of interventions (i.e. prevention, treatment 
of patients with HIV, and treatment of patients with AIDS); effectiveness 
(i.e. low versus high effectiveness); and quality of evidence (i.e. weak versus 
strong evidence). In the performance matrix, ‘0’ denotes the absence and 
‘1’  indicates the presence of a criterion level (see Appendix 1). Information 
on target group, gender of target group and type of intervention was 
identified from each intervention itself, whereas the information on 
effectiveness of intervention and quality of evidence on effectiveness were 
based on the review conducted by Pattanaphesaj and Teerawattananon [4]. 
Rank ordering of interventions 
Subsequently, we estimated the probability of selection of an intervention 
by using the logistic regression model derived from the DCE study [28]: 
Logit(P)  = ln [P/(1-P)] = β0 + β1-3 Target group + β4-5 Gender of target group 
  + β6-7 Type of intervention + β8 Effectiveness 
  + β9 Quality of evidence on effectiveness + ε        
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where P is the probability of an intervention being selected by the 
respondents, β0 is the constant term, βi (i=1-9) are the coefficients of the 
model indicating the probability of selection relative to the reference 
criterion level, and ε is the unobservable error term. The regression 
coefficients for all criteria were obtained from each of the three groups 
of stakeholders – policy makers, PLWHA, and community members – 
representedby VHVs during the DCE survey (These are listed in Appendix 2). 
Next, all interventions were ranked in order of their probability of selection.
Deliberative process
In the deliberative process, group discussions were independently 
organised between July and August 2009 with three groups of 
stakeholders: six policy makers at the national level who are heavily 
involved in health resource allocation decisions in Thailand specifically 
on HIV/AIDS (‘policy makers’);  six members of the Thai network for 
PLWHA, representing PLWHA groups at the regional level in Thailand 
(‘PLWHA’); and six community members who have been trained by 
public health providers to be the VHVs in Samutprakan province (‘VHVs’). 
Participants were selected purposively from each group of stakeholders 
on the basis of their participation in the previous DCE study to ensure 
that they were familiar with the DCE and priority setting process. Each 
group discussion began with a brief introduction of the purpose 
of the meeting. Next, participants were presented with the rank 
ordering of the interventions, and they were then asked whether 
they agreed with the rank and to provide their justifications. We then 
asked them to re-classify all interventions into three categories – based 
on the traffic-light analogy: ‘good candidates for implementation’ 
(green), ‘not good candidates for implementation’ (red), and ‘in- 
between’ (yellow). This re-classification was done through consen-
sus or, when necessary, through voting. In all steps, participants were 
encouraged by the researcher (SY) to discuss, bring in additional criteria, 
and share their opinions with justifications regarding their preferences. 
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Comparison of rankings
We compared the rank ordering of interventions before and after the 
deliberative process to explore the impact of deliberation by estimating 
the Spearman’s rank correlation coefficient.
Research ethics
This study was approved by the Institute for the Development of Human 
Research Protections, Ministry of Public Health, Thailand. All participants 
provided their written informed consent.
The rank ordering of the 40 HIV/AIDS interventions before and upon 
deliberation is presented in Table 1. As indicated by the ranking results 
before deliberation, the group of policy makers expressed a preference 
for preventive programs that are highly effective and target high 
risk groups such as men who have sex with men (MSM), injecting drug 
users (IDU), female sex workers (FSW), and HIV sero-discordant couples, 
with good quality of evidence on intervention effectiveness. The five 
interventions with the highest priority were voluntary counseling and 
testing (VCT) for IDU, street outreach for IDU, substitution treatment 
for IDU, improved sexual transmitted infection (STI) treatment services 
for IDU, and improved STI treatment services for HIV sero-discordant 
couples. 
Upon deliberation, the group of policy makers reinforced their preference 
for highly effective programmes that target high risk groups. Community 
-based education and programmes that target the youth or the general 
population (with the exception for those aimed at the improvement of 
STI treatment services) were not preferred. In the deliberative process, 
a number of additional  cr iteria were put for ward in addition 
to those identified in the DCE. The policy makers group proposed 
cost-effectiveness as an important additional criterion. This group 
Results
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also added the criteria of whether an intervention could be used 
for multiple purposes, and of safety. For example, a policy maker 
argued that introducing nucleic acid test screening for blood 
testing enables the Thai Red Cross Society to simultaneously investigate 
the existence of Hepatitis B and C with detecting HIV in the same 
specimen, thus creating added value. Also, a reliable blood donation 
system is very important to secure safety in Thailand in this respect. 
The other criterion mentioned was the importance of targeting 
health care workers at risk as a way of encouraging them to work 
with PLWHA in hospitals. This led to a change from the rank 10th 
of the post-exposure prophylaxis for health care workers before 
deliberation to ‘good candidate for implementation’ category, upon 
deliberation. 
The group of PLWHA expressed a strong preference for treatment or 
care for AIDS patients i.e. highly active antiretroviral therapy, and 
treatment for opportunistic infection and other palliative care, as elicited 
by the DCE study (Table 1). However, upon deliberation, PLWHA gave 
almost all of the 40 interventions the same priority. They argued that 
every intervention was important and should be implemented together 
to prevent HIV infection. This group of PLWHA also asked that more 
budget possibilities be found from several sources of funding to secure 
the programmes and that otherwise, HIV/AIDS programmes should be 
smaller in scope so policy makers can cover all programmes within limited 
budgets. 
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Table 1 The HIV/AIDS interventions’ ranking based on DCE, and the ranking 
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PLWHA suggested the availability of alternatives as an additional criterion. 
For example, improving STI treatment services was not seen as a priority as 
alternative services were available in hospitals. PLWHA strongly disagreed 
with considering cost-effectiveness as a criterion – they argued that if an 
intervention is effective, it should be implemented, and that financial 
considerations should not be important. PLWHA also prioritised interventions 
that target the general population rather than high risk groups, because 
interventions for the general population cover a larger segment of the 
population, and reflect their notion that everyone has equal risk of HIV 
infection. One participant argued: “If these (interventions) are the national 
policy, they should be implemented to everyone not only the high risk 
groups. This is because everyone is at equal risk of HIV infection. We are all 
the same”. 
The preferences of VHVs cohered largely with those of policy makers except 
for the target group of the interventions: VHVs preferred interventions 
that target the youth rather than high risk populations. Consequently, 
community-based education and improvement of STI treatment 
services for the youth were the highest priority (Table 1). This preference 
was also confirmed upon deliberation. VHVs introduced the number 
of beneficiaries as an additional criterion. One volunteer mentioned: 
“Mass media campaigns have an impact on lots of people in the 
society. So we think this intervention is beneficial for the society at large”. 
Furthermore, VHVs emphasised the need to adapt certain interventions 
to suit the groups targeted.
There was a significant correlation between the rank ordering before 
and after deliberation for policy makers (correlation coefficient 37%) 
and VHVs (46%). The correlation coefficient presents the consistency 
of results between the DCE ranking and deliberation ranking. No 
such significant correlation was found for the PLWHA. In addition, 
from the group discussions, we found that both policy makers and 
VHVs were generally positive about the ease of interpreting DCE 
results and the MCDA process, whereas PLWHA were generally 
negative because of the difficulty of the DCE questionnaire, which might lead 
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to a misunderstanding of the exercise among the respondents.
This study has experimented with the use of MCDA to guide priority 
setting of HIV/AIDS interventions in Thailand, on the basis of consultations 
with the relevant stakeholders, through a deliberative process.
 
This study revealed the important of five criteria included in the DCE 
(i.e. target groups of interventions, gender of target groups, type of 
interventions, effectiveness, and quality of evidence on effectiveness), 
and a number of additional criteria raised during the deliberative 
process (i.e. ethical and social concerns, cost-effectiveness, (non) availability 
of alternatives, number of beneficiaries, and inappropriateuse or 
abuse of interventions). This reflects that stakeholders consider multiple 
criteria in prioritising interventions. 
The abovementioned results highlight that MCDA has good potential 
to be used for the making of explicit prioritisation decisions. Also, we 
observed that the group of policy makers and VHVs - although not 
PLWHA respondents - applauded the systematic approach for priority 
setting, including the development of relevant criteria, the presentation 
of the performance of interventions against these criteria, and the 
deliberative process. Although MCDA seems difficult for PLWHA as 
they may not be familiar or comfortable to make trade-off decisions, 
the considerable overlap of the rank ordering before and upon 
deliberation in the group of policy makers and VHVs indicates that 
the quantifiable criteria used in the DCE partly reflect the concerns 
that stakeholders have in their intervention priorities. We believe that, 
through its explicit approach, MCDA contributes to the transparency 
and accountability of the priority setting process. Moreover, the provision 
of the DCE ranking reduces the stream of information that stakeholders 
Discussion
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need to absorb when prioritising many interventions simultaneously. We 
therefore advocate that the identification and weighing of quantifiable 
criteria (whether through DCE or any other technique) should also 
be considered as an integrated MCDA component.
The present application of MCDA seems especially useful for policy 
planning in the long run as it can set priorities among a large set of 
interventions without defining the allocation of resources in a precise 
fashion. This use, also labeled generalised priority setting, can have 
far-reaching and constructive influences on policy formulation in the long 
term [26]. In contrast, the use of MCDA as presented in this study may not  be 
useful for guiding highly contextualised decisions on the implementation 
 of a single intervention, since this requires a higher level of detail 
in terms of financial and budgeting considerations. 
This study has experimented with the inclusion of a process of deliberation 
in MCDA in a research environment. As of now, Thailand is stepping 
towards a routine application of MCDA to define its universal coverage 
benefit package. Observations of that process reveal that the inclusion 
of all relevant stakeholders right from the beginning of the MCDA process 
is imperative to its success [29]. 
    
Yet, we also observed a number of shortcomings in the use of MCDA 
in this study. First, DCE are cognitive demanding and may not be 
appropriate for all stakeholders. Most notably, PLWHA had difficulties 
in completing the DCE survey and interpreting the DCE findings. 
Further research is needed on the use of less cognitive demanding 
techniques than DCE that serve the same goal [30]. Second, our 
intervention set was relatively homogeneous in terms of the criteria 
covered in the DCE (e.g. effectiveness; quality of evidence on effectiveness; 
type of intervention), and this resulted in low variation in probabilities 
of inclusion. The application of DCE across different health conditions 
[15-19] is, in that respect, more powerful. Third, we did not engage 
all stakeholders in a single deliberative process to arrive at a consensus 
on the rank ordering of interventions, an adaption which would 
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represent the final stage of a successful priority setting process. However, 
the findings in this study can serve as a reflection of other stakeholders’ 
preferences for policy decision-making that may lead to greater acceptance 
of priority setting decisions. Moreover, this study can be considered 
a lesson learned process to other stakeholders, especially the general 
population who have never been involved in health policy decision- 
making, and can help them to understand how to set priorities for health 
interventions. In future priority setting research, it would therefore be 
valuable to incorporate these public perspectives.     
   
Although the set of criteria for MCDA may vary by country and health system 
context, the approach is generalisable to other settings. Furthermore, the 
MCDA criteria may be different if priority setting is required across different 
health problems e.g. infectious diseases, cardiovascular conditions, and 
mental health problems. Therefore, further exploration is warranted.
This study has documented the feasibility of MCDA to prioritising HIV/ 
AIDS interventions in Thailand, and has shown the usefulness of a deliberative 
process as an integrated component of MCDA. MCDA holds potential to 
contribute to a more transparent and accountable priority setting process, 
and further application of this approach in the prioritisation of health 
interventions is warranted. 
Conclusion
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Appendix 2 Discrete choice model results by perspective†
*Significant variables (p < 0.05)
†Source: Youngkong S, Baltussen R, Tantivess S, Koolman X, Teerawattananon Y: Criteria for priority setting of HIV/AIDS interventions in Thailand: A discrete choice experiment. BMC Health 
Service Research 2010, 10:197.
Criteria
Target group
Gender of target 
group
Type of 
intervention
Effectiveness
Quality of 
evidence
on effectiveness
Log likelihood
Pseudo R2
Hosmer-Leme-
show chi-square
(p-value)
Levels
Child
Teen
HiRrisk
Adults
Male
Female
BothGen
HIV
AIDS
Prevent
LoEff
HiEff
Weak
Strong
Coefficient
(95% CI)
 
1.049*
(0.445, 1.654)
1.153*
(0.502, 1.803)
0.023
(-0.470, 0.517)
 
-0.256
(-0.762, 0.250)
0.266
(-0.131, 0.663)
 
-0.493*
(-0.904, -0.081) 
1.967*
(1.450, 2.485)
 
1.983*
(1.643, 2.323)
 
1.310*
(0.976, 1.645)
-424.4532
0.2747
1.36
(0.995)
Coefficient
(95% CI) 
0.135
(-0.169, 0.440)
0.022
(-0.323, 0.368)
-0.279
(-0.575, 0.017)
 
0.082
(-0.184, 0.348)
1.132*
(0.911, 1.354)
 
1.091*
(0.869, 1.313)
0.212
(-0.052, 0.476)
 
0.627*
(0.454, 0.800)
 
0.356*
(0.183, 0.528)
-1434.3323
0.0992
2.79
(0.947)
Coefficient
(95% CI)
0.830*
(0.464, 1.196)
0.314
(-0.105, 0.734)
-0.249
(-0.609, 0.112)
 
0.196
(-0.123, 0.514)
0.724*
(0.458, 0.990)
 
-0.476*
(-0.744, -0.208)
0.246
(-0.078, 0.569)
 
1.185*
(0.973, 1.395)
 
0.349*
(0.139, 0.560)
-963.3818
0.0984
1.87
(0.985)
(p-value) 
(0.001)
(0.001)
(0.926)
 
(0.321)
(0.189)
 
(0.019)
 
(0.000)
(0.000)
 
(0.000)
(p-value) 
(0.385)
(0.900)
(0.065)
 
(0.544)
(0.000)
 
(0.000)
(0.116)
 
(0.000)
 
(0.000)
(p-value) 
(0.000)
(0.142)
(0.176)
 
(0.229)
(0.000)
 
(0.001)
(0.137)
 
(0.000)
 
(0.001)
Perspectives
Policy makers People living with HIV/AIDS Village Health Volunteers
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Introduction:   Considering rising health expenditure on the one hand, and 
increasing public expectations on the other hand, there is a need for explicit 
health care rationing to secure public acceptance of coverage decisions 
of health interventions. The National Health Security Office, the institute 
managing the Universal Coverage Scheme (UC) in Thailand, recently called 
for more rational, transparent and fair decisions on the public reimbursement 
of health interventions. This paper describes the application of multi-criteria 
decision analysis (MCDA) to guide the coverage decisions on including health 
interventions in the UC health benefit package, in the period 2009-2010.
Methods: We described the MCDA priority setting process through partici-
patory observation, and evaluated the rational, transparency and fairness 
of priority setting process against the Accountability for Reasonableness 
framework.
Findings: The MCDA was applied in four steps: 1) 17 interventions were 
nominated for assessment; 2) nine interventions were selected for further 
quantitative assessment on the basis of the following criteria: size of population 
affected by disease; severity of disease; effectiveness of health intervention; 
variation in practice; economic impact on household expenditure; 
and equity and social implications; 3) these interventions were then 
assessed in terms of cost-effectiveness and budget impact; and 4) 
decision makers qualitatively appraised, deliberated, and reached 
consensus on which interventions should be adopted in the package.
Conclusion: This project was carried out in a real-world context and has 
considerably contributed to the rational, transparent, and fair priority set-
ting process through application of MCDA. Although the present project 
has applied MCDA in the Thai context, MCDA is adaptable to other settings.
Abstract 
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High-cost health interventions including pharmaceuticals and medical 
technologies are increasingly becoming available in Thailand, increasing 
public and patient expectations. However, due to limited resources, the 
government cannot make all of those interventions available to the 
population and this makes the need for priority setting of interventions 
more and more explicit. In the past, decisions on the public reimbursement 
of interventions were typically ad-hoc and not transparent [1, 2]: 
e.g. certain interest groups (like politicians, health professionals or 
industry) could selectively advocate new interventions for public 
reimbursement.  The decis ion-mak ing processes of ten lack a 
systematic way without clear criteria for making coverage decisions. 
Decision makers in Thailand have recently acknowledged this 
inadequate process and called for more rational, transparent and fair 
decisions on the public reimbursement of interventions to improve 
population health in the country [3]. As a spring-off, the National Health 
Security Office (NHSO), the institute that manages the largest health plan 
in Thailand (Universal Coverage Scheme; UC), initiated a collaborative 
research and development project with two independent research 
institutes: the Health Intervention and Technology Assessment 
Program (HITAP), and International Health Policy Program (IHPP), in 
2009. The aim of the project was to develop an optimal strategy for 
the development of the UC benefit package, i.e. to determine which 
interventions should be candidate for public reimbursement.  
At the outset of the project, it was decided to use multi-criteria decision 
analysis (MCDA) as an overall methodological approach for its potential for 
rational and transparent priority setting [4, 5]. MCDA is defined as ‘a set of 
methods and approaches to aid decision-making, where decisions are based 
on more than one criterion, which make explicit the impact of all the criteria 
applied and the relative importance attached to them’ [5].
This paper describes the application of MCDA to support the coverage 
decisions on including health interventions in the Thai UC health 
Introduction
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Multi-criteria decision analysis
benefit package, in the period 2009-2010. We address the following research 
question ‘Does the use of MCDA lead to (more) rational, transparent and 
fair decisions in the development of the UC benefit package in Thailand?’ 
In the absence of clear standard on all aspects, we evaluate the present 
project against the accountability for reasonableness (A4R) framework 
[6, 7], that specifies conditions for fair decision-making. In doing so, the 
framework also considers the aspects of rational and transparent priority 
setting. 
To our knowledge, this is the first time in a low- or middle-income country 
that MCDA is practically used including a deliberative process and multiple 
stakeholders’ involvement to guide national-level priority setting in health 
care coverage decisions. The experience of Thailand, and therefore this 
paper, also holds relevance for other countries, as it may inform them on the 
options and limitations of MCDA for setting priorities in health.  
Decision-maker
Ad hoc Priority Setting Rational Priority Setting
Multi-criteria decision analsis
Severity of disease Average population health
Severity of disease
Average population health
Ease of implementation
Emergency situations
Burden of disease
Economic growth
Irresponsible behaviour
Vulnerable populations
Budget impact
Disease of the poor
Coat-effectiveness
Rank ordering of
interventions
1.
2.
3.
4.
5.
6.
7.
8.
Ease of implementation Cost-effectiveness
Emergency situations Political self-interestBurden of disease
Preferences of funding bodies
Irresponsible behaviour Diseases of the poor
Economic growth
Budget impact
Vuinerable populations
Global paradigms
Evidence-
based
medicine
Burden of
disease
analysis
Cost-
effectiveness
analysis
Equity
analysis
Evidence-
based
medicine
Burden of
disease
analysis
Cost-
effectiveness
analysis
Equity
analysis
Decision-maker
Figure 1 Ad hoc priority setting and rational priority setting
Source: Baltussen R, Niessen L (2006) Priority setting of health interventions: the need for multi-criteria decision analysis. Cost 
Effectiveness and Resource Allocation 4: 14.
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Empirical evidence suggests that a number of criteria including efficiency, 
equity (e.g. giving priority to the severely ill or the poor), financial 
protection and political considerations are considered important by policy 
makers when setting priorities [8-10]. However, it is far from easy for policy 
makers to consider these criteria simultaneously - evidence on all criteria 
is not always available, criteria are not equally important and may even 
conflict with each other, and policy makers (as people in general) are not good 
at absorbing dissimilar types of information, and risk cognitive overload 
[4]. This has prompted the use of MCDA for priority setting (Figure 1) 
[4]. MCDA allows the identification of a comprehensive set of criteria, 
establishes the performance of interventions on those criteria in a so-called 
performance matrix, and then inspects the performance matrix 
qualitatively or quantitatively to rank order interventions [4]. In a qualitative 
inspection, policy makers simply interpret the performance matrix, and 
make implicit judgments on the weights of the various criteria. In a 
quantitative inspection, policy makers weigh the different criteria 
on the basis of its relative importance, and multiply the score by the 
weights to obtain weighed averages for all interventions. Interventions 
can subsequently be rank ordered according to these weighed averages.
We described the MCDA priority setting process through participatory 
observation. We evaluated the rational, transparency and fairness of 
priority setting process against the Accountabilty for Reasonableness (A4R) 
framework [6, 7]. The framework specifies the four conditions for fair 
decision-making. In doing so, the framework also considers the aspects 
of rational and transparent priority setting. 
The whole process involved a project team (including NHSO, HITAP and 
IHPP) and a research team (including HITAP and IHPP). At the beginning of 
the project, the research team reviewed the international experience on 
the development of public health benefit packages to further refine and 
Methods
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operationalise the methodological approach. The review documented the 
experience of seven health technology assessment (HTA) organizations in 
Canada, England and Wales, the United States of America, the Netherlands, 
Germany, Sweden, and Spain, that all use an explicit process of priority 
setting (Table 1). The review concluded that all of these organizations 
consider multiple criteria, involve multiple stakeholders, and distinguish, in 
one way or another, four basic steps in their priority setting process. These 
steps were then also applied in the Thai setting and included: 1) nomination 
of interventions for assessment; 2) selection of interventions for assessment; 
3) technology assessment of interventions; and 4) appraisal of interventions.
For steps 1 and 2, the project team established a consultation panel (panel 
1) to reach consensus on who should be involved in these steps, and which 
criteria should be included as the selection criteria. Participants of the 
consultations were identified by their expertise and selected purposively to 
cover stakeholders who play an important role in the Thai health insurance 
system. The four steps are discussed in detail below. 
Step 1: Nomination of interventions for assessment
The consultation panel 1 reached consensus to include large variety of 
stakeholders in Step 1 reasoning that coverage decisions also have broad 
consequences for the population of Thailand. Consequently, the NHSO 
established a working group including representatives of seven groups of: 
policy makers (i.e. decision makers at Ministry of Public Health and other 3 
public health insurance schemes), health professionals (i.e. representatives 
from health professional associations), academics, patients, civil society (i.e. 
representatives from non-government organizations that are managed 
as permanent associations with legal status), industry (i.e. representatives 
from multi-international and local pharmaceutical companies, and medical 
devices industries), and lay people (i.e. citizen constituencies of the Thai 
National Health Assembly), but excluded international organizations and 
the researchers who conduct HTA as their interests may not reflect that 
of society. Each working group member was then assigned to propose 
a maximum of three interventions, including supportive information of 
the performance of these interventions on the established criteria. A total 
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of 17 interventions were nominated.
Step 2: Selection of interventions for assessment 
As to the selection criteria, the research team - through its review - identified 
a range of criteria that are being used internationally (Table 1). The research 
team made sure all criteria were scientifically sound and relevant to the Thai 
context. This list of criteria was put forward to the consultation panel 1 as 
an input for discussion. The panel initially agreed with considering the 
criteria that were frequently used in the HTA organizations. Upon consultation 
with the panel 1, consensus was reached on the use of six criteria: i) size of 
population affected by the disease; ii) severity of disease; iii) effectiveness 
of health intervention; iv) variation in practice; v) economic impact on 
household expenditure; and vi) equity/ethical and social implications. 
Subsequently, the research team worked with a second consultation panel 
(panel 2) including policy makers and academics to further develop these 
criteria (i.e. establishing its definitions and measurement). The panel agreed 
to score the performance of each intervention on each criterion on an 
ordinal scale from 1 to 5. The panel decided to give all criteria equal weight, 
and that this could be changed in the future when necessary. The results of 
the panel discussions are presented in Table 2. The criteria are discussed in 
turn below.
 - Size of population affected by disease. The size of the population 
  affected by the disease holds a positive relationship with the impact of 
  that disease for society, and is therefore an important criterion for 
  priority setting, the panel argued. As indicator, the panel agreed to use 
  the prevalence of the disease and scaled the prevalence on various 
  levels.
 
 - Severity of disease. Thai society generally gives high priority to 
  inter ventions that target the severely i l l  because of their 
  greater need for health care [11]. The panel defined the severity 
  of disease on the basis of health state valuations with a range 
  from 0 (worst health status) to 1 (best health status), and defined five 
  levels. Following a Thai study that showed that some people 
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  considered some health state worse than death [12], the panel 
  agreed that the lowest scale could be less than 0.
 - Effectiveness of health interventions. Effectiveness relates to the 
  outcomes of interventions and is a routinely-used criterion in priority 
  setting [13, 14]. Effectiveness is often expressed in quality-adjusted 
  life years (QALYs) but the panel did not consider this suitable for this 
  step because the effectiveness of interventions in terms of QALYs was 
  not available for all interventions, and could not make available within 
  the limited study period. Therefore, the panel created a separate scoring 
  system for three categories of interventions: treatment/rehabilitation 
  (giving higher priority to interventions that cure a disease than only 
  improve quality of life); screening/diagnostic (giving higher priority 
  to interventions with high accuracy (>60%) targeting a curable disease); 
  preventive (given higher priority to interventions that can prevent 
  more than 60% of a disease). 
 - Variation in practice. All Thai citizens are covered by a public health plan 
  (the Civil Servant Medical Benefit Scheme for civil servants, state 
  enterprise employees and their dependents; the Social Security Scheme 
  for private sector employees; the UC for the rest of the population). 
  Because these plans hold different agreements with health providers, 
  there is growing concern about the inequity in health services delivered 
  to beneficiaries of the different plans [15]. The panel acknowledged the 
  differences in intervention coverage between the health plans, and 
  across the country, and therefore the importance of this criterion. The 
  panel developed different scales to reflect variation in practice, taking 
  into account the source of evidence (local, national or international).
 - Economic impact of household expenditure. One of the objectives of 
  the UC is to protect household income from catastrophic health 
  expenditure [16, 17[. The literature defines catastrophic expenditure 
  as households’ spending on direct health care costs (e.g. medicines) 
  which exceeds 10% of household’s expenditure [15, 18, 19]. The panel 
  adopted this definition to establish the scoring scale of this criterion. The 
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Table 1 The results of the reviews regarding stakeholder involvement and criteria used
The reviewed organizations
NICE VATAP DAHTHCADTH SBUHealth 
council of 
the NL
CAHTH
Stakeholder involvement in nomination step
Policy makers
Health professionals
Academics
Patients
Civil society
Private sector
General population
International organizations
The researchers who conduct HTA
Stakeholder involvement in selection step
Policy makers
Health professionals
Academics
Patients
Civil society
Private sector
General population
International organizations
The researchers who conduct HTA
Criteria used in selection of health technology assessment topics
Variation
Resource impact
Necessity
Effectiveness
Efficiency
Cost of intervention
Individual responsibility
Translating new knowledge into clinical practice or care
Possibility of change in cost
Burden/severity of disease
Need for knowledge of the problem
Urgency/ timeliness
Number of potential patients
Policy importance
Equity/ ethical and social implications
Economic impact
Sufficient evidence for assessment
Criteria used in health intervention assessment
Effectiveness/ efficacy
Safety
Cost
Cost-effectiveness
Budget impact
Population impact
Planning/ utilization/ legal issues
Equity/ ethical and social implication
•••••••
•
•••••
•
•
••
•
•
•••
•
•
••••
••
•
•
•
•
••
•
•
•
•
•••••••
••••••
•
••
•
•
•
•
••
••••
•
•••
•
•
•
•
•
••
•
••••••
•••
•
•••
•
•
•
•
•
••
•
•
•
•
•
•••
•
•
•
•••
••
•
•
•
•••
•
••
••
•
NICE - the National Institute for Health and Clinical Excellence (England and Wales); CADTH - Canadian Agency for Drug and Technologies in Health (Canada); VATAP - Veteran Administration’s 
 Technology Assessment Program (the United States of America); SBU - Swedish Council on Technology Assessment in Health Care (Sweden); DAHTH - German Agency for Health Technology 
Assessment (Germany); CAHTH - Catalan Agency for Health Technology Assessment (Spain)
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  scale was established by dividing the 10% top rank of the average 
  household expenditure on health care (baht per year) from a national 
  household socio-economic survey in 2008 [20] into  quintile groups, 
  and then using the upper value of each expenditure interval for setting 
  the scores.
 - Equity/ Ethical and social implication. The panel considered ethical and 
  social implications of interventions to be important, and argued that 
  the poor and patients with rare diseases are - in a moral sense - more 
  deserving of health care than others. The panel decided that priority 
  should be given to diseases that are more frequent among the poor 
  (based on World Health Report 2002 that classifies poverty as a risk factor 
  of disease) [21]. In the absence of adequate definitions of ‘rare diseases’ 
  in Thailand, the panel decided to use the lowest prevalence level of the 
  criterion ‘size of population affected by disease’ (prevalence = 10,000) 
  as a threshold. 
As to the selection of interventions for assessment, the consultation panel 
(panel 1) determined to use the same working group as mentioned above 
but without the representatives of policy makers and industry (as they were 
considered to have a potential conflict of interest) and lay people (as they 
were considered difficult to identify, and to be adequately represented by the 
representatives from civil society), and this working group was established 
by the NHSO. 
The research team reviewed the 17 nominated interventions against the six 
selection criteria, and then presented all information to the working group. 
Because of limited and incomparable information on severity of disease 
for the nominated interventions, the working group decided to omit this 
criterion. The performances of the 17 interventions on the five remaining 
criteria were summarized in a performance matrix (additional file 1). Upon 
inspection and deliberation, they selected nine interventions for further 
assessment. Of these interventions, eight were selected because they 
scored best in the overall ranking. One intervention ‘absorbent products for 
urinary and fecal incontinence among disable and elderly people’ was added 
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because the target group was considered to be vulnerable and deserving 
of publicly funded health care. The NHSO’s Subcommittee for Development 
of Benefit Package and Service Delivery (SCBP), which includes multi- 
disciplinary stakeholders i.e. policy makers, health professionals, civil society, 
and patient groups, approved in May 2010 that these nine interventions 
would be subject of detailed assessment.
Table 2 Selection criteria
5 = higher than 500,000
4 = 100,001 – 500,000
3 = 50,001 – 100,000
2 = 10,001 – 50,000
1 = less than 10,000
5 = higher than 0.61
4 = 0.41 – 0.60
3 = 0.21 – 0.40
2 = 0.01 – 0.20
1 = less than 0
5 = cure
4 = prolong life & major improvement of QoL
3 = prolong life & minor improvement of QoL
2 = major improvement of QoL
1 = minor improvement of QoL
5 = accuracy > 80% & 
      screened disease could be cured
4 = accuracy 60 – 80% & 
      screened disease could be cured
3 = accuracy > 80% but 
      screened disease could not be cured
2 = accuracy 60 – 80% & 
      screened disease could not be cured
      or accuracy < 60% & 
      screened disease could be cured
1 = accuracy < 60% & 
      screened disease could be cured
Scoring 
Prevalence
Quality of life score
The clinical benefit of the 
proposed intervention and 
improvement in quality of life
Accuracy of the intervention 
and whether the screened 
disease could be cured
Parameter
Number of people affected 
by the disease or health 
problem that treated, or 
prevented by the proposed 
intervention among Thai 
population at a specified 
time.
Severity of disease or health 
problem that treated or 
prevented by the proposed 
intervention by considering 
its impact on the patients’ 
quality of life 
The final outcomes of the 
proposed intervention that 
benefit the patients with 
regard to objective of the 
intervention
3.1  For treatment/ 
rehabilitation:
Capacity of the proposed   
intervention to treat or 
rehabilitate the patients from 
the disease and its impact on 
the patients’ quality of life
3.2  For screening/ diagnostic:
 Quality of the proposed 
intervention to screen or 
diagnose the disease of the 
patients and the expected 
outcome beyond the 
screening or diagnostic
Definition
1. Size of population affected
by disease 
2. Severity of disease 
3. Effectiveness of health 
intervention
Criteria
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Table 2 (Continued)
5 = higher than 90%
4 = 81 – 90% 
3 = 71 – 80% 
2 = 61 – 70%
1 = less than 60%
5 = national evidence presenting variation in practice 
in Thailand
4 = national evidence presenting variation in practice 
in some areas
3 = international evidence presenting variation in 
practice in other countries that could assume there is 
variation in practice in Thailand
2 = no evidence but we could assume there is varia-
tion in practice in Thailand
1 = no variation in practice
5 = higher than 62,500 baht/year
4 = 35,601 – 62,500 baht/year
3 = 20,801 – 35,600 baht/year
2 = 12,000 – 20,800 baht/year
1 = less than 12,000 baht/year
5 = targeting the poor & prevalence < 1,000 
4 = targeting the poor & 
      prevalence 1,000 – 10,000
3 = targeting the poor & prevalence > 10,000
2 = not targeting the poor & 
      prevalence < 1,000
      or not targeting the poor & 
      prevalence 1,000 – 10,000
1 = not targeting the poor & 
      prevalence > 10,000
Scoring 
Effectiveness of the 
intervention to prevent 
the disease
The difference of the benefit 
packages between the 3 
health insurance schemes in 
Thailand
The difference of health 
interventions distribution
Direct medical and non-
medical household 
expenditure as a 
consequence of the disease 
or health problem per year
Disease of the poor
Prevalence < 1,000 (Rare 
disease)
Parameter
3.3 For prevention:
Risk reduction or preventive 
capacity provided by the 
proposed intervention to the 
population
Variation of implementing 
the intervention in practice 
that leads to unequal 
accessibility to the 
intervention among Thais. 
Variation in practice could be 
identified from the different 
coverage of the three 
publicly funded health 
insurance schemes in 
Thailand and/or could be 
identified from the different 
distribution of the
intervention throughout 
the country. 
Impact on household 
expenditure as a 
consequence of providing 
health intervention to a f
amily member with 
consideration of catastrophic 
illness or health catastrophe.
Priorities for specific groups 
of patients i.e. the poor with 
rare disease, reflect the moral 
values that should be consid-
ered by policy makers. 
Definition
4. Variation in practice 
5. Economic impact on 
household expenditure 
6. Equity/ ethical and social 
implication
Criteria
QoL – Quality of life; 
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Step 3: Technology assessment of interventions
The research team proposed another set of criteria (assessment criteria) 
for detailed assessment of the nine interventions. In addition to the review 
results from the international literature (Table 1), the research team also 
put forward results of a recent study on the criteria and its weight (elicited 
by Discrete Choice Experiments; DCE) for priority setting, as conducted 
in Thailand [22]. This study suggested the following criteria to be important: 
type of intervention (classified by the objective of intervention i.e. 
prevention or treatment), target group of intervention (classified by age 
group), severity of disease, number of beneficiaries, value for money, and 
budget impact. The research team considered all criteria, and argued 
that – because the assessment criteria in the present step follow-up on the 
selection criteria used in step 2 – overlap should be avoided. Upon careful 
assessment of all criteria and deliberation, the research team came to the 
consensus to use two assessment criteria: ‘value for money’ and ‘budget 
impact’. Because of the numerical nature of these two criteria, the research 
team decided they were not further scaled.  
 - Value for money. The criterion ‘value for money’ refers to the 
  maximization of health outcomes given a certain budget, and is an 
  often-cited criterion for priority setting [13, 14, 23]. The research team 
  defined the criterion in terms of incremental cost per QALY (so called 
  Incremental Cost-Effectiveness Ratio; ICER) to allow comparison 
  across a broad range of interventions.  
 
 - Budget impact. The research team considered affordability of inclusion 
  of an intervention in the UC benefit package to be important. This 
  criterion addresses the budget impact by estimating the financial 
  consequences of adoption and diffusion of a new intervention within 
  a specific setting, while considering the fiscal capacities of the health 
  plan [24, 25]. 
The SCBP then approved these two criteria to be used in the assessment. 
Subsequently, the research team assessed the nine interventions in terms of 
their value for money (ICER) and budget impact (Table 3), and collaborated 
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with external experts and relevant stakeholders for each intervention for that 
purpose. The ICERs were calculated following health economic evaluation 
guidelines in Thailand [26], and were therefore reliable and comparable. 
In addition, the SCBP also requested information of the performance of all 
nine interventions on the selection criteria (as discussed above) – these were 
also considered in the appraisal of the interventions.
Step 4: Appraisal of interventions
In the fourth step, in July-August 2010, the research team presented the 
results of the assessment of nine interventions to the SCBP for appraisal, i.e. 
for final decision on inclusion of interventions in the benefit package (Table 
3). The SCBP members elaborated upon these assessments, and discussions 
focused on three major issues: which costs were included in the models, 
whether the most cost-effective alternative intervention of each disease 
was already covered in the benefit package and whether the proposed 
intervention would be feasible for implementation. They considered 
a threshold of one time gross domestic product (GDP) per capita 
(approximately US$4,500 in 2010 [27]) per QALY gained as good value 
for money. Table 4 shows the relationship between the results of step 3 
(technology assessment) and those of step 4 (appraisal). Two out of nine 
interventions were analysed in terms of costs only (one of them was 
recommended by the SCBP), and their results are also not included in Table 
4. Of the other seven interventions, the SCBP agreed to recommend three 
interventions for further consideration to be adopted under the UC scheme 
(Table 4) because they were cost-effective with low budgetary impact. At 
the same time, for two out of these three interventions it was found that 
cost-effective alternatives were already covered under the benefit package 
(i.e. Lamivudine for treating people with chronic hepatitis B and Intravenous 
cyclophosphamide + Azathioprine for treating severe lupus nephritis). 
The other four interventions were not selected for a number of reasons. Some 
interventions (i.e. treatment for people with chronic hepatitis C, and absorbent 
products for urinary and fecal incontinence among disabled and elderly 
people) were cost-effective but the budgetary impact of the intervention 
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was considered too high. One intervention ‘anti-immunoglobulin E for severe 
asthma’ was not cost-effective with high budgetary impact. Finally, the 
intervention ‘implant dentures for people who have problems with 
conventional complete dentures’ was cost-effective but the SCBP denied 
to appraise it because there had been poor service accessibility to current 
alternatives that would first need to be solved. No intervention yielding ICER 
higher than 1 GDP per capita per QALY gained was recommended for the 
benefit package.
Table 3 Health intervention assessment results and policy recommendations 
Health interventions
1.  Treatment for people with 
chronic hepatitis B 
2.  Treatment for people with 
chronic hepatitis C
3. Treatment for severe lupus 
nephritis 
Cost-utility analysis
Lamivudine (produced by GPO) 
is the most cost-effective 
(cost-saving) compared to 
palliative care and to the other 
alternatives;
- Lamivudine (original), 
- Adefovir + Lamivudine (GPO), 
- Entecavir, 
- Telbivudine, and 
- Pegylated interferon alpha 
Pegylated interferon alpha 2a 
(Peg2a) + Ribavirin for treating 
hepatitis type C subtype 1, 4, 5, 
and 6 is the most cost-effective 
(ICER=THB 86,600/QALY) com-
pared to palliative care and to 
other alternatives; 
- Interferon alpha + Ribavirin, 
Peg2a + Ribavirin, Pegylated 
interferion alpha 2b (Peg2b) 1 g/1 
kg of body weight + Ribavirin, 
Peg2b 1.5 g/1 kg of body weight 
+ Ribavirin
Intravenous cyclophosphamide 
(IVC) + Azathioprine (AZA) for 3 
years is the most cost-effective 
(cost-saving) compared to the 
standard treatment for treating lu-
pus nephritis (IVC with decreasing 
dose for 3 years), and to the other 
alternatives (i.e. IVC + Mycophe-
nolate mofetil (MMF) for 3 years, 
MMF + AZA for 3 years, MMF with 
decreasing dose for 3 years).
Policy recommendations 
The most cost-effective 
intervention for treating chronic 
hepatitis type B, Lamivudine, has 
already been covered under the 
benefit package.
Not recommended because of 
high budget impact.
The most cost-effective interven-
tion for treating lupus nephritis 
(i.e. IVC 1,000 mg/month for 6 
months and then AZA 50 mg/day 
for further 2.5 years) has already 
been covered under the benefit 
package. 
Budget impact analysis
The budget of providing 
Lamivudine (GPO) is THB 50 
million higher than providing 
palliative care in a first year of 
implementation, and will 
increase to THB 500 million at the 
5th year.
Providing Peg2a for treating 
hepatitis type C subtype 1, 4, 5, 
and 6 is increasing budget by THB 
3,500 million. Providing Peg2b for 
treating hepatitis type C subtype 3 
is increasing budget by THB 8,600 
million. Therefore, it would be in 
total THB 12,000 million within 
5 years.
Budget of treatment is
approximately THB 1.4 – 1.5 
million per patient
Results*
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Table 3 (Continued)
4. Smoking cessation program 
5. Anti IgE for severe asthma 
6. Implant dentures for people 
who have problem with 
conventional complete dentures 
7. Absorbent products for urinary 
and fecal incontinence among 
disabled and elderly people 
8. System for screening, treatment 
and rehabilitation of alcoholism 
9. Screening for risk factors for 
leukemia in people living in the 
industrial areas
Every intervention for smoking
cessation is cost-effective 
(cost-saving) (i.e. counseling at 
the hospital, counseling by quit 
line, counseling + nicotine gum, 
counseling + nicotine patch, 
counseling + Bupropion, 
counseling + Nortriptyline, and 
counseling + Varenicline) 
compared to no intervention
(suddenly quit smoking by 
themselves; smokers).
Omalizumab (anti IgE) is not cost-
effectiveness (ICER= THB 414,503/
QALY) compared to standard 
clinical practice guideline (Steroid) 
for severe asthma.
Implant dentures is cost-effective 
(ICER=THB 5,147/QALY).
Absorbent product is cost-effec-
tive (ICER= THB 54,000/QALY).
N/A
N/A
All interventions for smoking 
cessation are cost-effective. 
Therefore, the program is 
recommended for further 
consideration to be adopted in 
the benefit package. 
Not recommended because it is 
not cost-effective intervention and 
the budget estimation per year is 
very high.
Not recommended because 
problems of access to standard 
treatment of dental care were still 
unsolved
Not recommended because of 
high budget impact
Not recommended because of 
inadequate information (in 2010)
Recommended for further 
consideration to be adopted in 
the benefit package because the 
problem causes considerable loss 
in terms of cost of illness at THB 
3,500 million in 30 years.
In case of providing Nortriptyline 
(as a first line drug) 80% + Nicotine 
gum 10% + Varenicline (as a 
second line drug) 10%, the budget 
would be THB 273 million in a first 
year and would increase to THB 
566 million at the 5th year.
Providing Omalizumab to treat 
severe asthma patients increases 
budget by THB 54,000 million per 
year, and will increase the budget 
by THB 270,000 million within 
5 years.
The 5-year budget will be THB 
280 – 781 million on the basis of 
expected target population, and 
will be THB 83 – 208 million based 
on human resource (health profes-
sionals) capacity.
Budget of providing absorbent 
products to the disabled and 
elderly is approximately THB 4,800 
million per year.
N/A
N/A (the researchers estimated 
social costs of illness instead: from 
the model of 50,000 populations 
who are living in the indus-
trial areas with migration of 1,000 
people per year, social costs of 
illness would be THB 3,500 million 
in 30 years)
GPO: the government pharmaceutical organization; SLE: systemic lupus erythematosus; IgE: immunoglobulin E; ICER: Incremental cost-effectiveness ratio; QALY: Quality adjusted life year; 
THB: Thai baht; N/A: Not available.
*In 2010, 1 US dollar is approximately 30.17 baht [Bank of Thailand. Foreign Exchange Rates as of 29 December 2010. 
www.bot.or.th/Thai/Statistics/FinancialMarkets/ExchangeRate/_layouts/Application/ExchangeRate/ExchangeRate.aspx].  
Health interventions Cost-utility analysis Policy recommendations Budget impact analysis
Results*
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*Two cost analysis studies, i.e. screening for risk factors for leukemia in people living in the industrial areas, and system for screening, treatment and rehabilitation of alcoholism, are not 
included in this table.
**High budget impact >THB 200 million per annum; low budget impact ≤ THB 200 million per year
ICER: Incremental Cost-Effectiveness Ratio; GDP: Gross domestic product; QALY: Quality-adjusted life year
Whether this use of MCDA indeed improved rational, transparency and 
fairness of the priority setting process in Thailand is not easy to judge in the 
absence of a clear standard on all these aspects. As an alternative, we evaluate 
the project against the accountability for reasonableness (A4R) framework 
[6, 7], that specifies conditions for fair decision-making: reasonableness, 
publicity, revisable, and enforcement. In doing so, the framework considers 
aspects of rational and transparency at the same time. 
The reasonableness condition states that the rationale for priority setting 
decisions must rest on evidence and principles that are accepted as 
relevant by fair-minded people. In the present project, contributing 
elements in this were the following: both selection and assessment criteria 
were identified and approved by a large variety of stakeholders (including 
consultation panel 1, the research team and the SCBP) on the basis of 
literature review and careful elaboration, and supported by a previous study 
Table 4 The relationship between assessment and appraisal results
Policy
recommendation
Recommended
Not recommended
Low budget impact**
• Lamivudine for treatment 
for people with chronic 
hepatitis B
• Intravenous 
cyclophosphamide + 
Azathioprine for treating 
severe lupus nephritis
• Smoking cessation 
program
• Implant dentures for 
people who have problem 
with conventional 
complete dentures
High budget impact**
• Pegylate interferon alpha 
2 a + Ribavirin for treating 
hepatitis C
• Absorbent products for 
urinary and fecal 
incontinence among 
disabled and elderly 
people
Low budget impact
Assessment results*
Cost-effectiveness
(ICER ≤ 1 per-capita GDP/QALY)
Not cost-effectiveness
(ICER > 1 per-capita GDP/QALY)
High budget impact
• Anti immunoglobulin E for 
severe asthma
- -
-
-
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on priority setting criteria in Thailand [22]. In addition, the definition and 
scales of the criteria were adapted to the Thai context, and the performance 
of interventions on every criterion was supported by available local evidence. 
Also, the nomination, selection for assessment and final priority setting 
was based on elaboration among a wide variety of stakeholders in working 
groups – the latter is described as a key aspect of fair processes (28). Limiting 
elements were that the project did observe some difficulties in the working 
groups as to identify truly representatives of various stakeholders, e.g. that 
of lay people. Also, while the project involved a range of stakeholders in its 
consultation panels and working groups in steps 1-3, the SCBP eventually 
made decisions itself and it is not sure to what extent the final decisions 
still reflect the stakeholders’ preferences.  
The publicity condition prescribes that rationales for priority setting 
decisions must be publicly accessible. The present project communicated 
information on criteria and the selection of interventions for assessment 
to stakeholders and the general public through newsletter, chapters in the 
newspaper, formal letters, and organizational websites. However, the reasons 
underlying the final decisions regarding the adoption of interventions in 
the package were not explicitly acknowledged. As a result, the working 
groups had requested the SCBP to provide them an official letter explaining 
why particular interventions were in- or excluded in the benefit package, 
and subsequently, the SCBP reluctantly accepted it. Although this is a way 
of sharing the message to the public, there is a need for an assessment of 
the effectiveness of this mode of communication in the future. The revisable 
condition allows for challenging the decisions and giving opportunities for 
revision and improvement of policies in the light of new evidence. Yet, the 
present project did not have a systematic appeal mechanism to challenge 
the coverage decisions. Nevertheless, the process information and the criteria 
involved in the original decision are publicly accessible and allow the general 
public to express their dissatisfaction. This can lead to reconsidering the 
decisions in light of new evidence and better arguments. The enforcement 
condition can be either voluntary or regulation of the process to ensure that 
the first three abovementioned conditions are met. Based on the one-year 
experience, there was no rule and regulation to reach this condition.
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This research and development project, initiated by NHSO in Thailand, and 
is a first attempt to achieve rational, transparent and fair health care 
rationing through the application of MCDA in a real-world context. MCDA 
was applied in the various steps throughout the project to identify (selection 
and assessment) criteria, to construct performance matrixes and to elaborate 
on these before coming to final conclusions. Although it is difficult to judge 
in the absence of quantified standards, MCDA seems to have considerably 
contributed to fairness in priority setting. The merits of MCDA are especially 
clear when the present process is compared to the situation before where 
priority setting was said to be ad-hoc and driven by interests of stakeholder 
groups.
Deliberation is an important component of MCDA. Whereas the performance 
matrix quantifies the performance of interventions on selected criteria, 
the consideration of other criteria (that cannot be quantified or were for 
other reasons missing in the performance matrix) is vital in MCDA and is 
captured in the process of deliberation. As an example, the intervention 
‘absorbent products for urinary and fecal incontinence among disabled 
and elderly people’ was selected for assessment, even though its score was 
not in the top rank. In the present project, criteria like ‘vulnerability’, ‘a more 
cost-effective alternative’, and ‘feasibility of implementation’ were put forward 
in the deliberation process in step 2 (selection of interventions for assessment). 
This paper described the first year of experience only of the use of 
MCDA to develop the UC benefit package, and did not capture the final 
coverage decisions. The SCBP is now consulting with the tobacco research 
and knowledge management center in Thailand to make the ‘smoking 
cessation program’ part of the tobacco prevention program. Likewise, the 
SCBP is now consulting with the NHSO’s department of health promotion and 
disease prevention to incorporate the screening programme for leukemia 
in their regular work. Both interventions still need further consideration 
before they can be covered under the UC scheme. As to the ‘absorbent 
products for urinary and fecal incontinence among disabled and elderly 
Discussion
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people’, initially the SCBP members seemed to support coverage of this 
intervention upon the ethical aspects, i.e. the clear need for this intervention 
when the assessment was on-going in 2010. This intervention was finally 
denied by the SCBP for inclusion because of its large budget impact (SCBP 
meeting in July 2011). 
Our study has a number of limitations. First, the scoring scales of some 
criteria were difficult to define, such as targeting the poor and those with rare 
diseases. A clear definition of both terminologies was lacking; therefore, in 
this project, the definition and scoring scales development were determined 
on the basis of experts’ opinion and the international guideline i.e. World 
Health Report 2002 [21]. Although these two information sources are 
acceptable, country-specific and more reliable evidence for creating the 
criteria’s and the scoring scales’ definition should be developed. Second, we 
found a lack of comparable evidence of each intervention on the severity of 
disease criterion. As it would be costly and time consuming to conduct an 
empirical study for all proposed interventions, only partial information and 
expert opinion on this criterion was considered. While severity of disease 
has been widely used in priority setting to balance between equity and 
efficiency in many settings [29-31]; this limitation has led to a doubt in 
using this criterion in MCDA. Hence, this flags serious attention for its further 
measurement. Third, some criteria, like effectiveness, were difficult to 
understand for non-academic people – this constituted a barrier to 
achieving consensus in group discussions as lay people were dominated 
by higher educated people. The project however did not consider this reason 
to delay involving the public in the process of priority setting, and informed 
all stakeholders as much as possible on the way. Fourth, all criteria used 
in this project were determined to carry equal weights, which may not 
reflect the local values in reality. Although the relative weights of criteria 
analyzed from the DCE were considered by the research team and the SCBP, 
they were not used directly - weighing of criteria may be considered in future 
projects. Then, the question should also be addressed how the potentially 
divergent weights from the various stakeholders can be accommodated. 
Fifth, the framework of A4R was purposively selected to evaluate the 
prioritization process of the project. However, there are other evaluation 
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tools that can be applied for assessing the resource allocation process such 
as a framework of internal and external parameters for evaluating successful 
priority setting in low and middle income countries [32], and a checklist for 
assessing nine common themes of good practice for health research priority 
setting [33].
It is noteworthy that a decision making on itself is a dynamic process, and 
some intervention performance on some criteria used e.g. severity of disease, 
effectiveness of interventions, or economic impact of household expenditure 
are likely to change overtime. For example, changing population structure 
can lead to increase or decrease of some disease incidence, or availability 
of new intervention can lead to the change of costs of existing intervention. 
This can be drawn from the case of ‘Pegylate interferon alpha 2a and 
Ribavirin for treating hepatitis C’ that was not recommended at the initial 
decision making because of its high budgetary impact. However, at the end 
of 2011, this combined intervention for treating hepatitis C was eventually 
included in the benefit package because the lower price of the intervention, 
due to extensive price negotiation between the Thai Ministry of Public Health 
and pharmaceutical companies, resulted in a lower budget impact. Hence, 
priority setting of interventions is a continuous process. It also means that 
some interventions that failed to be prioritized in the first place may need 
to be reconsidered again in the future as they may become priorities then.
Although the present project has applied MCDA in the Thai context, MCDA 
– as a general approach - is applicable or adaptable to other settings. This 
would require identification of priority setting criteria as relevant to that 
setting, including assigning weights and/or scores for each criterion, and the 
assessment of performance of all interventions on these criteria, to arrive 
at a context-specific priority setting process. That would then not only in 
Thailand but also in other settings lead to decisions that are more rational, 
transparent and fair.
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Appendix 1 Scores of the proposed health interventions against the selection criteria
The reviewed organizations
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1. Anti-immunoglobulin E for severe asthma
2. Treatment for people with chronic hepatitis B
3. System for screening, treatment and rehabilitation of alcoholism
4. Implant dentures for people who have problem with 
 conventional complete dentures
5. Screening for risk factors for leukemia in people living in 
 the industrial areas
6. Treatment for severe lupus nephritis 
7. Smoking cessation program
8. Treatment for people with chronic hepatitis C
9.  Absorbent products for urinary and fecal incontinence 
 among disabled and elderly people
10.  Treatment for infertilized women
11.  Renal replacement by dialysis for new final stage renal 
 failure patients
12.  Screening and treatment for liver cancer
13.  Physical examination package (following the Civil Servant 
 Medical Benefit Scheme)
14.  Cissus quadrangularis L. for hemorrhoid
15.  Biological agents for psoriasis
16.  Screening for gall bladder cancer
17.  Orbital implant and Plastic surgery of orbit and facial bones
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*Severity of disease was omitted from the criteria list in the first year of the project (2010).
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This commentary responds to the article by Goetghebeur et al., which applies 
the EVIDEM (Evidence and Value: Impact on DEcision-Making) framework to 
evaluate growth hormone therapy for Turner syndrome patients. While we 
value the qualities of the EVIDEM because of its scope and breadth, we have 
doubts on the results consistency of the EVIDEM to compare competing 
interventions, particularly when setting priorities across broad healthcare 
service areas (e.g. in designing the national health benefit package) for two 
main reasons. First, the EVIDEM framework ignores the contextual nature of 
priority setting process by assuming a set of universal priority setting criteria. 
Secondly, the EVIDEM is vulnerable to interventions ranking inconsistency 
where performance evaluation of a broad range of competing interventions 
is mandated. To address its limitations, we propose a stepwise process to 
identify criteria and their weights, and rank ordered interventions. 
Abstract 
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This commentary responds to the article by Goetghebeur et al [1], which 
applies the EVIDEM (Evidence and Value: Impact on DEcision-Making) 
framework to evaluate growth hormone therapy for Turner syndrome 
patients. The EVIDEM framework is developed to assist decision-makers 
in healthcare decisions, and encompasses a multi-criteria decision analysis 
(MCDA) matrix consisting of 15 quantifiable, and six qualitative components 
of decision. With this comprehensive set of criteria, relevant experts can 
assess the performance of health interventions, and results are input for 
informed and transparent healthcare decisions. 
Goetghebeur et al [1] propose that the EVIDEM can be used to compare 
various interventions across disease areas in order to prioritize interventions. 
They suggest that the EVIDEM can analyze single interventions, and the 
performance of competing interventions can subsequently be compared in 
a performance matrix. While we value the qualities of the EVIDEM because 
of its scope and breadth, we have doubts on the results consistency of the 
EVIDEM to compare competing interventions, particularly when setting 
priorities across broad healthcare service areas (e.g. in designing the national 
health benefit package) for two main reasons. 
First, the EVIDEM framework ignores the contextual nature of priority 
setting process by assuming a set of universal priority setting criteria [2]. 
In reality, the priority setting process is context specific and different sets 
of criteria lead priority setting of health interventions in different contexts. 
As the examples of studies in Nepal [3], Chile [4], and Ghana [5] show, the 
set of criteria identified for using in priority setting of health interventions 
were different between countries. Therefore, we suggest that the setting of 
prioritization criteria needs to be locally determined or verified, implying 
that the EVIDEM needs to be flexible to allow change/modification of the 
components to suit the local context. 
Secondly, the EVIDEM is vulnerable to interventions ranking inconsistency 
where performance evaluation of a broad range of competing interventions 
Commentary
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is mandated. For example, the EVIDEM framework requires different expert 
panels to assess the performance of every single intervention separately. 
This may lead to inconsistency of the results as different expert panels may 
have different considerations across the broad range of interventions to 
be assessed. As shown in the EVIDEM Turner Syndrome case study [1], the 
panel of experts estimated growth hormone intervention to achieve 41% of 
maximum value. However, in the absence of established explicit weights of 
criteria, it is not certain that the same panel will be consistent in evaluating 
different interventions, or that another panel of experts comes up with the 
same or similar value. 
These arguments raise the question whether the approach of EVIDEM is 
locally meaningful and consistent when priorities are set for a range of 
interventions. To address its limitations, we propose a stepwise process to 
identify criteria and their weights, and rank ordered interventions. 
We suggest that, to set priorities of a range of interventions within a certain 
context, a locally-meaningful set of criteria and their relative importance 
(i.e. weights) should be elicited by consulting relevant stakeholders. As a 
next step, the identified set of criteria and weights are then used to 
consistently assess the performance of the broad range of interventions. 
To illustrate the method, we describe a study in Thailand [6], which defined 
explicit criteria to prioritize health interventions for the national health 
benefit package. Our study was conducted in five main steps. First, in 
a group discussion among multi-stakeholders, the six most important 
prioritization criteria (and their levels) were identified i.e. type of intervention, 
target groups of intervention, severity of disease, number of beneficiaries, 
value for money, and budget impact. This step ensured that the criteria 
were verified for the Thai context. Second, based on those six criteria, we 
designed a discrete choice experiment (DCE) questionnaire, an approach 
that facilitates MDCA, and distributed this among 24 national health 
policymakers, 55 health professionals, and 163 general populations. Third, 
our DCE analyses resulted in odds ratios (OR) per criterion level (i.e. target 
group criterion contains three levels: elderly, adult and children). The 
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OR indicated the relative importance of incremental changes in criterion 
levels (compared to a reference level), to select an intervention (Table 1). For 
example, policymakers are 5.73 times more likely to select health 
interventions that target the children than interventions targeting the 
elderly. In this way the criteria and their weights were the same for every 
health intervention, and ranking consistency was achieved. Fourth, from the 
DCE results, we calculated the interventions’ probability of being selected, 
by combining the performance of interventions on each criterion and the 
importance of that criterion. The probability of being selected resulted 
in a rank ordering of health interventions. Fifth, the rank ordering was an 
important input in an elaborative process among policymakers. In the study, 
we presented the different rank orderings from those three perspectives of 
stakeholders to policymakers for more elaborative discussion. This included 
consideration of non-quantifiable criteria in reaching consensus on the final 
health interventions priority list for the national health benefit package.
The explicit weighing of criteria analyzed from DCE may improve the 
consistency of priority setting across contexts and over time, but does 
not solve the more fundamental problem that views of stakeholders, and 
therefore their expressed criteria and weights, may diverge. This is 
acknowledged by the ‘Accountability for Reasonableness’ (A4R) framework 
[7, 8] which is based on the believe that any consensus on priority setting 
weights and subsequent results may be difficult to achieve because of these 
distinct perspectives of stakeholders. Instead of attempting to resolve the 
problem of diverse stakeholders’ views, the A4R framework proposes to 
concentrate on a fair priority setting process. On this basis, when conditions 
of reasonableness, publicity, appeal and enforcement are satisfied, it would 
lead to decisions that are considered fair and acceptable to stakeholders. 
In our view, exploring how stakeholders’ divergent perspectives on the 
weighting of criteria can be met fairly, is an object for further research.   
In summary, the framework of EVIDEM can be a useful tool to assess single 
intervention or to prioritize between only few interventions; however, in this 
paper, we place emphasis on the potential of DCE for consistently setting 
priorities between a range of interventions at once and its meaningfulness 
across different contexts.  
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Table 1 Relative importance (Odds ratios) of criteria by perspective
Criteria
Type of intervention
Target group of intervention
Severity of disease
Number of beneficiaries 
Value for money
Budget impact
Log likelihood
Pseudo R2
General 
population
1.56*
1.13
1.41
2.40*
2.45*
2.48*
2.06*
2.80*
9.35*
1.51*
12.96*
4.25*
-2301.6025
0.2055
Health
professionals
     
  2.50*
1.22
1.88
3.93*
2.92*
4.24*
6.00
8.64*
23.27*
2.28*
27.97*
4.43*
-637.7022
0.3341
Policy
makers
**
**
**
3.71*
5.13*
6.29*
43.42*
19.97*
48.91*
1.35*
31.60*
9.91*
-199.5608
0.5065
Perspectives (Odds ratios)
Levels
Prevention for non-communicable diseases
Prevention for communicable diseases
Treatment for non-communicable diseases
Treatment for communicable diseases
Elderly
Adult
Children
Not severe
Moderate severe
Severe
Few 
Many 
High cost but low effectiveness
High cost and high effectiveness
Low cost and low effectiveness
Low Cost but high effectiveness
High budget impact
Low budget impact
*Significant variables (p < 0.05)
**Removed variable
Note: 
1. The odds ratios were overestimated because of the small sample size of policy makers. However, there was no any relevance for the interpretation of the results.
2. The group of policy makers expressed higher preference on the high cost and highly effective interventions rather than the low cost with highly effective ones. The explanation of this 
is reported elsewhere.
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This paper capitalizes on a ﬁrst set of experiences on the application of 
multi-criteria decision analysis (MCDA) in seven low-and middle-income 
settings. It thereby reacts to a recent paper by Peacock et al., highlighting the 
potential of MCDA to guide policy makers in highly speciﬁc decision-making 
contexts. We argue that MCDA also has a broader application in setting 
priorities in health, i.e. to indicate general perceptions on priorities without 
deﬁning the allocation of resources in a precise fashion. This use of MCDA 
can have far-reaching and constructive inﬂuences on policy formulation. 
Priority setting,  Multi-criteria decision analysis 
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This paper capitalizes on a ﬁrst set of experiences on the application of 
MCDA in seven low-and middle-income settings [1–7], building upon the 
conceptual basis of MCDA in health as described elsewhere [8]. It thereby 
responds to a recent paper by Peacock et al. [9] in this journal, in which 
the authors elaborate on the use of interdisciplinary methods to set 
priorities in health, and thereby highlight the potential of MCDA. We 
qualify a number of observations by Peacock et al. [9] on the types of policy 
questions MCDA can address, and on methodological aspects of MCDA. 
We also elaborate on the construction of a global database on intervention 
priorities. 
Priority setting is sometimes referred to as a generic process on the rank 
ordering of interventions [10], but in reality covers a wide variety of policy 
questions at different levels of the health system. We distinguish two 
broad applications of priority setting studies: ﬁrst, priority setting can be 
undertaken to inform policy makers in a speciﬁc context on e.g. the 
reimbursement of a single intervention, or to prioritize between only a few 
interventions, either at the national, sub-national or institutional level in 
a country. These decisions are taken in the presence of a known budget 
and might be limited by factors such as the currently available physical 
infrastructure, human resources or political consideration, at least in the 
short-to medium-term [11]. We label this ‘context-speciﬁc priority setting’. 
These are also the type of policy questions Peacock et al. [9] refer to, and 
that programme budgeting and marginal analysis (PBMA) has traditionally 
and successfully addressed in a large number of studies in the past [12]. 
Indeed, as Peacock et al. [9] suggest, MCDA can play a role in this process 
to make decision-makers objectives and their value trade-offs consistent 
and transparent. 
Introduction
Types of policy questions 
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The second application of priority setting studies in a country, which goes 
beyond the scope of PBMA [9],is to guide decisions on a wide range of 
interventions, to provide general information on their relative rank ordering 
to arrive a more informed debate on resource allocation priorities. 
Because it is not meant to provide a solution to a speciﬁc resource 
allocation question, it need not be highly contextualized in terms of e.g. 
physical infrastructure and/or human resources constraints. Such general 
perceptions on priorities can have far-reaching and constructive inﬂuences 
on policy formulation, deﬁning the set of options that are debated 
without deﬁning the allocation of resources in a precise fashion. We label 
this ‘generalized priority setting’ (cf. Murray et al. [13]). In this context, 
MCDA can serve different aims. It can e.g. be used to elicit and deﬁne 
general, national-level, criteria for priority setting (and indicate their relative 
importance). The deﬁnition of such criteria makes the rationale of 
national-level priority setting decisions explicit, and thereby adds to the 
accountability and transparency of its process [14]. It follows up on the 
example of the Dunning committee in the Netherlands, that deﬁned a 
funnel including four sieves (necessity, effectiveness, cost-effectiveness, 
and self-responsibility) that interventions need to pass to be included in a 
national insurance package [15]. As another example, Ghana has used criteria 
as identiﬁed through MCDA, to set its intervention priorities in the Ghana 
Health Sector Plan of Work 2007–2012 [3]. 
One step further, and perhaps the most important contribution of MCDA 
in the realm of generalized priority setting, is to provide broad classiﬁcations 
of interventions within a speciﬁc disease area. Applications include priority 
setting in HIV/AIDS control in Thailand [4], and across a broad set of 
interventions to guide decisions at the national-level in Ghana [1,3], China [5], 
Brazil [6], and Cuba [7]. However, because of its nature, MCDA can weigh the 
relative importance of quantiﬁable criteria only, and an initial rank ordering 
of interventions may only be based on those. Yet, it is obvious that any 
priority setting process should also account for non-quantiﬁable criteria 
such as ethical judgments [16], and these can be accounted for through a 
process of elaboration. In such a process, intervention ranks are discussed and 
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can be modiﬁed, and this has been successfully tested in the prioritization 
of HIV/AIDS interventions in Thailand [4]. The resulting rank ordering – 
taking into account both quantitative and qualitative criteria – can then 
be a useful basis for policy making. Yet, such a ranking should never be 
interpreted in a formulaic sense given the political economic realm in 
which priority setting is taking place [11], and which may add further 
(irrational) criteria to the process. Instead, the resulting rank order of 
interventions might be best presented in three classiﬁcations: those that 
are ‘priorities’, those that are ‘not priorities’, and those that are in 
between (cf. classiﬁcation of HIV/AIDS interventions in Thailand, Center 
for Global Development [17]).  This information provides policy 
makers with broad indications of intervention (groups) that may 
be candidates for implementation (to foster the transparency 
of results, the performance of intervention on the individual criteria 
should also be made avai lable to pol ic y makers) .  Again,  the 
availability of such information adds to the accountability and 
transparency of the priority setting process [14]. 
Whereas PBMA, by its nature, is in the literature typically related to 
‘context-speciﬁc priority setting’, some exceptions exist. For example, 
an Australian study to guide decisions on the inclusion of eight 
interventions in the next cancer control strategy has been referred to 
as a PBMA study, while the study only provided broad descriptions of 
criteria and broad indications on the overall  attractiveness of 
interventions [20]. However, what is or is not a PBMA study may not 
be of prime importance here, and may be an issue of semantics. Most 
important observation here is the conceptual distinction between 
‘context-speciﬁc priority setting’ and ‘generalized priority setting’, and 
Peacock et al. [9] highlight the importance of participatory action research, 
and the involvement of stakeholders in decisions on intervention priorities. 
Methodological aspects 
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The inclusion of perspectives of relevant stakeholders – and where possible 
the achievement of consensus – is indeed important, to improve 
accountability, credibility and acceptability of results by society [14,18,19]. 
The recent MCDA study on the prioritization of HIV/AIDS interventions 
in Thailand followed up on this, and revealed important differences between 
preferences of policy makers, people living with HIV/AIDS, and lay people 
[4]. The study did not aim to reach consensus between the stakeholders, 
and within the studies referred to above, there is no experiences yet 
on how to do so. It is not sure whether the process of elaboration may 
be useful in this respect given the risk of dominance of one group of 
stakeholders (less-experienced e.g. lay people) by another (well-educated 
and more-experienced e.g. policy makers). 
The recent experiences show that different studies have identiﬁed different 
 criteria for priority setting. This may reﬂect real differences in preferences 
between countries, but may also reﬂect differences in methodological 
approaches. Some studies [1–4] identiﬁed criteria through focus group 
discussions, and relevant criteria may be omitted because they have not 
been put forward strong enough or because participants may have simply 
forgotten to mention them. Other studies identiﬁed criteria on the basis 
of theory and the literature reviews [5–7,21], which may result in sets of 
different criteria than those relevant in the study context. One way forward is 
the deﬁnition of a comprehensive list of criteria – on the basis of the present 
experience and other literature – which is then elaborated upon in detail in 
e.g. a focus group discussion. This approach is currently being conducted 
in a MCDA priority setting study in Thailand, and proves an effective way 
to reduce the risk of omission of relevant criteria while also improving 
comparability of study results between studies (see below). 
On the one hand, there will never be enough resources available to elicit 
preferences for criteria in all countries in the world. On the other hand, 
Towards a global database on intervention priorities 
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Peacock et al. [9] have highlighted the usefulness of MCDA in context- 
speciﬁc priority setting, and we emphasize the potential of MCDA in 
generalized priority setting. First case-studies show the potential of MCDA 
to deﬁne general, national-level, criteria for priority setting, and provide 
broad classiﬁcations of intervention priorities. Important methodological 
challenges remain vis-à-vis the inclusion of different stakeholders and 
a comprehensive set of criteria. The construction of a global database 
would enable countries around the world to strike a balance between 
efﬁciency and equity in their prioritization of health interventions. 
Conclusion
a single set of preferences for criteria would not adequately reﬂect 
socio-economic and cultural variations explaining these preferences. 
A question of interest is then whether general patterns exist on the 
preferences for priority setting criteria (both on the type of criteria, and 
their relative importance) between countries. Multi-country studies could 
provide an answer to this, and ﬁrst explorations are taking place. On the 
basis of such studies, a global database on the prioritization of  interventions 
could be established, following the example of a WHO-CHOICE database 
on the cost-effectiveness of interventions [22], but then taking into 
account multiple criteria. This would then also involve the collection of 
evidence on the performance of interventions on those criteria. The 
resulting rank ordering of interventions, including quantitative criteria 
only, would then give national-level policy makers (very) broad guidance 
on the relative priority of interventions. Where more detailed is required 
(sub-)country level analysis should be performed.
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The thesis includes a number of studies to guide priority setting of health 
interventions in Thailand, all using multi-criteria decision analysis (MCDA) 
as a common approach. Together the studies contribute to the definition of 
an optimal strategy for priority setting in Thailand.
This final chapter responds to overall research question “What is an optimal 
strategy to prioritise health interventions in Thailand?” through its responses 
to the three research sub-questions as defined in the Introduction in Chapter 
1. It then provides a number of practical recommendations for an optimal 
strategy to prioritise health interventions in Thailand, and to enhance the 
potential use of MCDA in the Thai context. Finally, limitations of this thesis 
and the need for further research are addressed. 
What is the current situation in priority setting in low- and 
middle-income countries?
Chapter 2 reviewed the empirical studies on priority setting of health 
interventions, and summarised its characteristics and methodological 
approaches in low- and middle-income countries (LMIC) in the past decade. 
The review found that methods for explicit priority setting (e.g. MCDA, 
accountability for reasonableness - A4R, and the balance sheet method) are 
all in development. In combination with increasingly available evidence of all 
sorts on diseases and related interventions, these methods can potentially 
be solutions for the ad hoc policy making on priority setting in health care in 
many LMIC. Yet, most of the studies included in our review were small pilot 
studies and did not include an evaluation of the impact of its ﬁndings on 
actual priority setting. Only when such information becomes available, clear 
recommendations to scale up certain methods can be given.
The review led to a number of reflections on the current situation in priority 
setting in LMIC. 
1) Most of the studies in this review involved multiple stakeholders in their 
General discussion
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 priority setting process. This concurred with observations in the literature 
 [1-4] that stressed the need to involve the views of other stakeholders in 
 addition to those of policy makers, especially that of the public, in debates 
 on rationing to enhance the legitimacy and fairness of decision-making. 
2) Some studies involved only a limited number of quantitative criteria, 
 whereas observations in the literature [5, 6] stressed that many other 
 criteria, including medical (e.g. effectiveness of interventions and 
 severity of disease) and non-medical (e.g. economic efﬁciency, ethical 
 reasons and political circumstances) criteria, may also be important 
 and relevant. In addition, some studies identiﬁed criteria through 
 literature review, whereas the relevance of criteria is likely to be dependent 
 on culture and perspective. 
3) A number of studies relied solely on quantitative techniques, such as 
 discrete choice experiments (DCE), to elicit preferences of respondents. 
 Where the advantage of such techniques is that its results can be 
 applied across interventions, their disadvantage is that not all criteria 
 that are relevant to priority setting are amenable to quantiﬁcation (not 
 only ethical and social acceptability but also more practical considerations 
 like intervention complexity) and these techniques then fall short of 
 capturing these [7]. A number of studies used qualitative techniques such 
 as deliberative processes. Such techniques have the advantage that 
 they are also able to address non-quantitative concerns and that they 
 explicitly allow the inclusion of views of different stakeholders [8] and 
 the achievement of consensus [7]. The disadvantage is that its results are 
 only relevant to the interventions under study and cannot be generalized 
 across interventions. 
4) A number of studies presented their results in mere descriptive format 
 such as identiﬁed criteria or respondents’ preferences, whereas studies 
 on priority setting have the intrinsic aim to rank-order interventions, 
 or more speciﬁcally, to identify interventions that should be included or 
 excluded from, e.g. public reimbursement [6]. 
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The abovementioned review allowed us to provide a number of suggestions 
on the various aspects of the methodological approaches to be used in 
developing the conceptual framework of the following chapters, on the basis 
of a comparison of the review’s ﬁndings to observations on good priority 
setting practice in the literature. 
1) Involving relevant stakeholders in priority setting process is 
 recommended. 
2) Identifying a comprehensive set of criteria through focus group 
 discussions with relevant stakeholders is probably a better approach 
 to obtain a suitable set of criteria. 
3) Quantitative techniques such as DCE may be relevant to situations 
 where general guidance on priority setting is required and that qualitative 
 techniques may be more apt in situations where more speciﬁc decisions 
 are required on, e.g. implementation of certain interventions (cf. Murray 
 et al. 2000 [9] on the need for generalized vs. highly contextualized 
 cost-effectiveness analysis). 
4) Priority setting study should present its final results in a rank-ordering 
 of interventions or, more specifically, identifying interventions that 
 should be included or excluded from, e.g. health benefit package.
In Thailand, cost-effectiveness analysis and burden of disease are often 
studied in isolation to promote rational priority setting in health care. As 
an example, Chapter 3 estimated the burden of Shigellosis on the basis of 
the economic impact of the disease. The cost estimates were based from 
137 episodes of 130 patients, and the average public treatment cost was 
US$8.65 per episode based on 2006 prices. Although of interest on itself, 
this information provided insufficient guidance to policy makers for making 
a coverage decision. It concentrated on a single technical solution only (i.e. 
burden of disease – in this case) whereas in reality, policy makers need to 
make choices on interventions taking other criteria (e.g. effectiveness, equity, 
or affordability) into account simultaneously [5, 6, 10-13]. 
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What is the implementation process of MCDA in Thailand?
 
MCDA was used as an overall framework in the two case studies: to set 
priorities in HIV/AIDS control; and to define the health benefit package in 
the Universal Coverage (UC) scheme in Thailand. 
a)  How to define priority setting criteria? 
 Chapter 4 identified criteria for priority setting of HIV/AIDS interventions 
 in Thailand using the perspective of policy makers, people living with 
 HIV/AIDS (PLWHA), and community member represented by village 
 health volunteers (VHVs). It revealed that different stakeholders had 
 different preferences vis-à-vis those criteria. We argue that inclusion of 
 different perspectives is important, to enhance the accountability of the 
 priority setting decisions. The case study of HIV/AIDS in this chapter 
 was a first step to integrate different views by documenting differences 
 and similarities.
 The DCE in this case study only included the criteria that were found to 
 overlap from the focus group discussions. The rationale for doing so was 
 to accommodate comparability of study findings (so to include identical 
 criteria in DCE for the various stakeholders) on the one hand, while 
 maintaining the number of criteria to a manageable number (thus not 
 including all possible criteria that were put forward by any discussion 
 group) on the other hand. However, this choice may have led to the 
 omission of important criteria for some groups of stakeholders, and may 
 have reduced the validity of study findings. To strike a balance between 
 comparability and validity, a group discussion among relevant 
 multi-stakeholders on the basis of literature review and careful 
 elaboration seems a more appropriate method to ensure that all relevant 
 criteria are identified for the Thai context, as demonstrated in Chapter 6 
 and 7. 
b)  How to rank order interventions?
 Chapter 5 experimented with the use of MCDA to guide priority 
 setting of HIV/AIDS interventions in Thailand, on the basis of consultations 
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 with the relevant stakeholders, through a deliberative process. We initially 
 rank-ordered 40 HIV/AIDS interventions on the basis of their probabilities 
 of inclusion calculated from the DCE results in Chapter 4. However, since 
 the DCE design only involved a set of criteria amendable to quantification, 
 it ignored a range of non-quantifiable considerations – e.g. ethical, 
 political, and social concerns. As such, any rank ordering of interventions 
 could be indicative only, and should never be interpreted in a 
 mathematical manner. A deliberative process was able to include the 
 non-quantitative criteria and has likely encouraged participatory 
 approaches with a variety of stakeholders and interests. Yet, chapter 5 
 also highlighted that the provision of the DCE ranking reduced the stream 
 of information that stakeholders needed to absorb in prioritising many 
 interventions simultaneously. As also shown in this chapter, a broad 
 clustering or typology of interventions as ‘priorities’, ‘not priorities’, 
 and ‘in-between’ was a good way to present results to policy makers. 
 Such a broad typology was then a starting point for a more detailed 
 priority setting process, in which policy makers could still deviate from 
 the broad recommendations. 
 Although we did not engage all stakeholders in a single deliberative 
 process in this case study to arrive at a consensus on the rank ordering of 
 interventions – which would be the final stage of a successful priority 
 setting process – the findings in this study could be a reflection of other 
 stakeholders’ preferences for policy decisions that may lead to greater 
 acceptance of priority setting decisions. 
 Chapter 6 described the first-year experience in applying MCDA as an 
 overall methodological approach to develop the UC health benefit 
 package in Thailand. MCDA was used in the various steps throughout 
 the case study to identify priority setting criteria (for the selection and 
 assessment of interventions), to construct performance matrixes, and to 
 elaborate on these before coming to final conclusions on the coverage 
 of health interventions in the UC scheme. 
 Although it was difficult to judge in the absence of quantified standards, 
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 MCDA seemed to have considerably contributed to fairness in priority 
 setting as defined in the A4R framework [14, 15]. This framework specified 
 conditions for fair decision-making: reasonableness, publicity, revisable, 
 and enforcement. The merits of MCDA were especially clear when the 
 priority setting process of this case study was compared to the situation 
 before where priority setting was said to be ad-hoc and driven by 
 interests of stakeholder groups. 
 Again, it was evident that deliberation was an important component 
 of MCDA. Whereas the performance matrix quantifies the performance 
 of interventions on selected criteria, the consideration of other criteria 
 (that cannot be quantified or were for other reasons missing in the 
 performance matrix) is vital in MCDA and is captured in the process of 
 deliberation. 
  
 In Chapter 7, we evaluated EVIDEM (Evidence and Value: Impact on 
 DEcision-Making) [16], a tool employing MCDA as its conceptual 
 framework, in its ability to set priorities across a range of interventions. 
 We expressed doubts on the consistency of its results when EVIDEM 
 compares a large set of interventions, for two main reasons. Firstly, the 
 EVIDEM framework ignores the contextual nature of priority setting 
 process by assuming a set of universal priority setting criteria. Secondly, 
 the EVIDEM is vulnerable to interventions ranking inconsistency when 
 different (sets of ) interventions are evaluated over time. 
c)  What are the challenges in the implementation process of MCDA?
 This thesis has identified a number of challenges in using MCDA for 
 priority setting of health interventions: 
 
 1)  Challenges related to the methodology used for identifying criteria 
  and measuring the weight of each criterion. This thesis employed DCE 
  to identify and measure the relative importance of various criteria 
  for priority setting of health interventions among various stakeholders. 
  We observed a number of shortcomings in the use of DCE in the 
  thesis.  
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	 	 •	 The	design	of	DCE	only	allows	inclusion	of	a	set	of	criteria	amendable	 
   to quantification, and a resulting rank ordering of interventions 
   presented in the performance matrix is then only based on those. 
   Yet, it is obvious that any priority setting process should also account 
   for non-quantifiable criteria such as ethical judgments [12], and these 
   cannot be captured through the sole use of DCE. 
  
	 	 •	 DCE	is	cognitive	demanding	[17-19]	and	may	not	be	appropriate	for	 
   all stakeholders - most notably in Chapter 4 and 5, people living 
   with HIV/AIDS had difficulties in completing DCE survey and 
   interpreting the DCE findings. 
	 	 •	 The	 findings	of	Chapter	5	 showed	 the	homogeneity	of	 the	 
   intervention set in terms of the criteria covered in the DCE, and 
   this resulted in low variation in probabilities of inclusion. The 
   application of DCE on interventions targeting the same health 
   condition is in that respect less powerful.
 2)  Challenges related to the information used for constructing the 
  interventions’ performance matrixes as a component of MCDA
  
	 	 •	 The	scoring	scales	of	some	criteria	were	difficult	to	define,	such	as,	 
   in Chapter 6, targeting the poor and those with rare diseases. The 
   definition and measurement of both criteria was challenging; 
   therefore, in this thesis, these were determined on the basis of 
   experts’ opinion and international guidelines (i.e., World Health 
   Report 2002 [20]). Although these two information sources are 
   somehow acceptable, country-specific and more reliable evidence 
   for creating the criteria and the scoring scales’ definition should be 
   developed.
	 	 •	 A	 lack	of	 comparable	evidence	of	each	 intervention	on	 the	 
   severity of disease criterion was found in Chapter 6. While severity 
   of disease has been widely used in priority setting to balance 
   between equity and efficiency concerns in many settings [21-23]; 
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   this limitation has led to doubts in using this criterion in MCDA. 
   Hence, this flags serious attention for its further measurement.
 
 3) Challenges related to decision-context
  
	 	 •	 Some	criteria	used	in	MCDA,	like	cost-effectiveness,	are	difficult	to	 
   understand for non-academic people – this constituted a barrier to 
   achieving consensus in group discussions as the general population 
   may be dominated by higher educated people.
	 	 •	 Decision	making	is	a	complex	process,	and	resource	allocation	is	 
   inherently political. Although a comprehensive set of criteria have 
   been elicited in priority setting process, policy makers at national 
   level still required room to elaborate their own reasons in the final 
   step to keep their power and authority in decision making. As shown 
   in Chapter 6, the reasons underlying the final decisions regarding 
   the adoption of interventions in the package were not explicitly 
   acknowledged. 
How is MCDA best used for priority setting in Thailand?
Chapter 8 capitalized on a first set of experiences on the application of 
MCDA in LMIC (i.e., Ghana, China, Brazil, Cuba, and Thailand). It reasoned 
that MCDA seems useful for policy planning in the long run, to set priorities 
among a large set of interventions. It thereby indicates general perceptions 
on priorities without defining the allocation of resources in a precise fashion. 
This use, also labelled generalized priority setting, could have far-reaching 
and constructive influences on policy formulation in the long term. In 
addition, there is the other type of priority setting that can be undertaken 
to inform policy makers in a specific context on e.g. the reimbursement of a 
single intervention, or to prioritise between only a few interventions, either 
at the national, sub-national or institutional level in a country. This is labelled 
context-specific priority setting. 
Lesson learned from the two case studies in the thesis provides ample 
evidence that MCDA was useful in Thailand in these two broad applications; 
i.e., to provide broad classifications of interventions within a specific disease 
area (Chapter 4 and 5), and across a broad set of interventions to guide 
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decisions at the national-level (Chapter 5 and 6), plus to guide highly 
contextualized decisions on the implementation of a number of interventions 
for the health benefit package (Chapter 6). 
The findings in chapters 2 – 8 address a number of issues of practical 
guidance and areas of further research to improve the use of MCDA for 
priority setting in Thailand. The challenge for priority setting is that there 
is no gold standard to judge the adequacy of prioritisation decisions made 
as interest views and therefore priorities of stakeholders may diverge. This 
is acknowledged by the ‘Accountability for Reasonableness’ (A4R) framework 
which is based on the belief that any consensus on priority setting weights 
and subsequent results may be difficult to achieve because of these 
distinct perspectives of stakeholders. Instead the A4R framework proposes to 
concentrate on a fair priority setting process. On this basis, when conditions 
of reasonableness, publicity, appeal and enforcement are satisfied, it would 
lead to decisions that are considered fair and acceptable to all stakeholders 
(as discussed in Chapter 6).  The thesis proposes a stepwise process of 
priority setting on the basis of the first experience on applying MCDA in 
priority setting in Thailand (Figure 1), that include the fair notions. Details 
on (some of ) the steps are shown below.
1
Process Output
3
5
2
4
6
Establishing a panel of relevant stakeholders
Eliciting a set of criteria by consulting the panel
Identifying the relative importance of the set of criteria by using DCE
or other techniques
Assessing the performance of the broad range of interventions
on the basis of the identified criteria and weights
Calculating the interventions’ probability of being selected
Arranging deliberative process among decision-makers
A locally meaningful set
of criteria
A performance
matrix
Relative weights of
the criteria
A rank ordering of health
interventions
Consensus on the
final health interventions
priority list
Figure 1 A stepwise process of priority setting of a range of interventions 
thesis-chapter9.indd   152 4/5/2555   13:19:59
General discussion
153
•	Multiple stakeholders involvement
Strengthening rational priority setting in health care, not only requires an 
explicit set of criteria, but also the involvement of all relevant multiple 
stakeholders in the process of priority setting. Observations of 
priority setting process in the case studies revealed that the inclusion of 
all relevant stakeholders right from the beginning of the MCDA 
process is imperative to its success. This is to include all relevant 
perspectives to improve legitimacy of final decisions, but also a way 
to educate other stakeholders who never had experience on making 
health pol ic y decis ions especial ly  the general  population to 
understand how to set priorities for health interventions. However, 
the problem of diverse stakeholders’ views exists. Therefore, exploring 
how stakeholders’ perspectives diverge on identifying criteria, 
and how these can be consolidated in a consensus on the rank 
ordering of interventions, is an object for future priority setting research.
•	Scoring system and relative weights of criteria
To assess the performance of the competing interventions in the 
performance matrix, it is important to have adequate estimate of the 
relative weights of criteria and to assess how interventions score on 
the criteria. This thesis employed two ways to score interventions: 
i) a dichotomous scale (i.e., scoring ‘0’ or ‘1’ to denote the absence 
or presence of a criterion level, as presented in Chapter 5); and ii) an 
ordinal scale (e.g., from 1 to 5 to indicate the scoring level of each 
intervention on each criterion, as shown in Chapter 6) and it is not 
clear which one is most suitable. Lessons learned from Chapter 5 and 6 
suggest that establishing an explicit definition of the criteria and 
its measurement are important steps in assessing the interventions’ 
performance. 
On the weights of criteria, the findings from Chapter 4 and 5 illustrate 
the feasibility of using DCE in determining the relative weights of 
criteria for priority setting. From this first experience of using 
DCE in this manner, it is clear that experimental design plays a vital 
role in the performance of a DCE. Therefore, determining an optimal 
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design for this cognitive demanding technique should be considered in 
further research. Besides DCE, there are a number of methods that 
can be used to weigh the criteria. Probably, further research is also 
needed on the use of less cognitive demanding techniques than DCE 
that serve the same goal.
•	Comparable local evidence 
The thesis illustrated a lack of comparable evidence of interventions 
on criteria, and in particular severity of disease in Chapter 6 because 
of the variation in methods used to estimate severity of disease. This 
led to doubt in using severity of disease as a criterion in the case 
study. Lesson learned from Chapter 5 and 6 suggest that although 
a set of criteria is identified and their relative importance are elicited, 
the reliability of MCDA results cannot be guarantee if there is no 
comparable local evidence for supporting the assessment of the 
interventions’ performance. Therefore, country-specific and more 
reliable evidence should be developed in a uniform methodology.  
• A combination of MCDA and deliberative process
Whereas the provision of MCDA reduces the stream of dissimilar 
information by assessing the interventions’ performance on a set of 
criteria in the per formance matrix,  the consideration of other 
non-quantifiable (or otherwise absent) criteria that did not present 
in the performance matrix for any reason is captured in the process 
of deliberation. Decisions on health intervention priorities should be 
made by using MCDA, on the basis of consultations with the relevant 
multiple stakeholders through a deliberative process. Therefore, 
a combination of quantitative and qualitative approaches is recommended. 
 
The studies presented in this thesis has applied MCDA in the Thai context 
and its findings may be not generalized to other health care settings. 
However, MCDA – as a general approach – and all recommendations above 
are applicable or adaptable to other settings.
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Summary
Priority setting of health interventions is one of the most challenging and 
difficult issues faced by health policy decision makers around the world. 
It is especially relevant and important in low- and middle-income 
countries (LMIC), where health needs are large and resources are limited. 
Thailand, as one of LMIC, has acknowledged this challenge and called 
for more rational priority setting of health interventions to improve 
population health in the country.
Chapter 1 introduces the need for rational approaches in priority setting, 
taking into account a comprehensive set of relevant criteria simultaneously. 
The main research question of this thesis is “what is an optimal strategy to 
prioritise health interventions in Thailand?”. To answer this question, three 
research sub-questions are defined and these are responded to in the 
different chapters.
1. What is the current situation of priority setting of health 
interventions in LMIC?
The systematic review of empirical priority setting studies in LMIC 
(Chapter 2) evaluated the current situation of priority setting of health 
interventions in LMIC. This review revealed an increasing number 
of empirical studies on priority setting in LMIC in the past decade. Yet, 
most of them were small pilot studies and did not include an evaluation 
of the impact of its findings on actual priority setting. Most studies 
identiﬁed sets of relevant criteria for priority setting and involved different 
stakeholders as respondents. Studies used qualitative or quantitative 
techniques, or combinations of these to elicit preferences from 
respondents. In a few studies, respondents deliberated on results. A minority 
of studies resulted in a rank ordering of interventions. This review 
illustrated that methods for explicit priority setting are in development, 
and can potentially lead to solutions for ad hoc priority setting in health 
care in many LMIC.
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In Thailand, cost-efffectiveness analysis and burden of disease are often 
studied in isolation to promote rational priority setting in health care. 
Chapter 3 presented a study that reported on a single criterion for priority 
setting, i.e. economic impact of a disease (i.e., Shigellosis). Although 
of  interest on itself, this provides insufficient information to guide policy 
makers for making a coverage decision. In reality, policy makers need 
to make choices on interventions taking a number of criteria (e.g. 
effectiveness, equity, or affordability) into account simultaneously. This 
has led to an interest of using multi-criteria decision analysis (MCDA) in 
health priority setting in Thailand.
2. What is the implementation process of MCDA in Thailand? More 
specifically: a) how to define priority setting criteria?; b) how to rank 
order health interventions?; and c) what are the challenges in the 
implementation process of MCDA?
MCDA was used as an overall framework in the two case studies: to 
set priorities in HIV/AIDS control (Chapter 4 and 5); and to define the 
health benefit package in the universal coverage (UC) scheme in 
Thailand (Chapter 6). 
Chapter 4 identified criteria for priority setting of HIV/AIDS interventions 
in Thailand using the perspective of policy makers, people living with 
HIV/AIDS (PLWHA), and community members represented by village 
health volunteers ( VHVs). On the basis of these, discrete choice 
experiments (DCE) were designed to determine the relative importance 
of criteria for priority setting among 28 policy makers, 74 PLWHA, and 
50 VHVs. The results of DCE revealed that different stakeholders have 
different preferences vis-à-vis these criteria (i.e., target group of 
intervention, gender of target group of intervention, type of intervention, 
effectiveness, quality of evidence on effectiveness). The findings of 
Chapter 4 were used to prioritise 40 HIV/AIDS interventions in 
Chapter 5. The chapter has documented the feasibility of MCDA to 
prioritise HIV/AIDS interventions in Thailand by incorporating an 
explicit component of deliberation to let stakeholders reflect on the 
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rank ordering, and adapt where necessary. This also shows the usefulness 
of elaborative process as an integrated component of MCDA.
Chapter 6 described the first experience in applying MCDA as an overall 
methodological approach to develop the UC health benefit package 
in Thailand, in the period 2009 – 2010. MCDA was used in the various 
steps throughout the case study to identify priority setting criteria 
(for the selection and assessment of interventions), to construct 
performance matrixes, and to elaborate on these before coming to 
final conclusions on the coverage of health interventions in the UC scheme. 
We evaluated the project against the accountability for reasonableness 
(A4R) framework, and found that MCDA has considerably contributed 
to rational, transparent and fair priority setting. 
In Chapter 7, we evaluated EVIDEM (Evidence and Value: Impact on Decision-
Making), a tool employing MCDA as its conceptual framework, in its ability 
to set priorities across a range of interventions. Then we proposed a 
stepwise process on the basis of the first experience on priority setting 
case studies in Thailand. 
The thesis has identified three major types of challenges in using MCDA 
for priority setting of health interventions: 1) challenges related to the 
methodology used for identifying criteria and measuring the weight of 
each criterion (i.e., DCE in this thesis); 2) challenges related to the 
information used for constructing the interventions’ performance matrixes 
as a component of MCDA; and 3) challenges related to the decision-context. 
3. How is MCDA best used for priority setting in Thailand?
From the first set of experiences on the application of MCDA in LMIC, 
MCDA seems useful for two purposes: generalized and context-specific 
priority setting (Chapter 8). Lesson learned from the two case studies in 
the thesis provides ample evidence that MCDA is indeed useful to provide 
broad classifications of interventions within a specific disease area 
(Chapter 4 and 5), and across a broad set of interventions to guide 
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decisions at the national-level (Chapter 5 and 6), plus to guide highly 
contextualized decisions on the implementation of a number of 
interventions for health benefit package (Chapter 6). The findings of this 
thesis have shown that MCDA has good potential to be used for 
explicit priority setting decisions that contributes to the transparency 
of the priority setting process.
In the General discussion (Chapter 9), the main findings are discussed. 
It then provides a number of practical recommendations and areas of 
further research to enhance the potential use of MCDA in Thailand. Since 
there is no gold standard to judge the adequacy of prioritise decisions, 
we refer to the A4R framework that focuses on a fair process instead. 
In addition, we propose a stepwise process of priority setting on 
the basis of the first experience on applying MCDA in priority 
setting in Thailand. This includes: i) establishing a panel of relevant 
stakeholders; ii) eliciting a locally meaningful set of criteria by consulting 
the panel; i i i)  identifying the relative importance of the set of 
criteria by using DCE or other techniques; iv) assessing the performance 
of the broad range of interventions on the basis of the identified set 
of criteria and weights; v) calculating the interventions’ probability 
of  being selected to rank ordering the inter ventions;  and vi) 
arranging deliberative process among decision makers (multi- 
stakeholder based) to reach consensus on the final health interventions 
priority list.
The studies presented in this thesis has applied MCDA in the Thai context 
and its findings may be not generalized to other health care settings. 
However, MCDA – as a general approach – and all recommendations 
provided in the thesis are applicable or adaptable to other settings. 
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Samenvatting
Wereldwijd is het prioriteren van gezondheidsinterventies een van de 
moeilijkste en meest uitdagende kwesties voor beleidsmakers in de 
gezondheidszorg. Dit is vooral relevant in landen met een laag- en 
middel inkomen (LMIC), waar de vraag naar gezondheidszorg groot is 
maar de middelen beperkt zijn. Een van die landen, Thailand, is deze 
uitdaging aangegaan en heeft opgeroepen tot een rationelere manier 
voor het prioriteren van gezondheidsinterventies om zo de volksgezondheid 
te bevorderen.
In Hoofdstuk 1 komt de behoefte aan een rationele aanpak voor het stellen 
van prioriteiten ter sprake, waarin tegelijk rekening wordt gehouden met 
een uitgebreid pakket relevante criteria. De belangrijkste onderzoeksvraag 
van dit proefschrift is “wat is een optimale strategie voor het prioriteren 
van gezondheidsinterventies in Thailand?”. Om deze vraag te kunnen 
beantwoorden zijn drie deelvragen ontwikkeld die in de verschillende 
hoofdstukken worden beantwoord.
1.  Wat is de huidige situatie wat betreft het prioriteren van 
gezondheidsinterventies in LMIC?
Het systematische review over prioriteringsstudies in LMIC (Hoofdstuk 
2) heeft de huidige situatie wat betreft het prioriteren van gezond-
heidsinterventies in LMIC in kaart gebracht. Deze studie liet een toename 
zien in het aantal empirische studies over het stellen van prioriteiten 
in LMIC in de laatste t ien jaar.  Echter,  het  merendeel  betrof 
kleinschalige pilotstudies die een evaluatie van de invloed van de 
bevindingen op de werkelijke prioritering niet hebben meegenomen. 
De meeste studies stelden relevante criteria voor het prioriteren vast 
en betrokken verschillende belanghebbenden als deelnemers. Studies 
maakten gebruik van zowel kwalitatieve als kwantitatieve technieken 
of combinaties hiervan om voorkeuren van deelnemers uit te lokken. In 
een aantal studies hebben de respondenten overlegd over de resultaten. 
Een minderheid van de studies resulteerde in een rangorde van interventies. 
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Dit review laat zien dat  methoden voor het expliciet stellen van prioriteiten 
in ontwikkeling zijn, en dat deze mogelijk kunnen leiden tot oplossingen 
voor het ad hoc stellen van prioriteiten in de gezondheidszorg in vele 
LMIC.
In Thailand worden kosteneffectiviteitsanalyses en ziektelast vaak 
afzonderlijk bestudeerd om het stellen van rationele prioriteiten in de 
gezondheidszorg te bevorderen. Hoofdstuk 3 presenteert een studie 
die één enkel criterium voor het prioriteren rapporteerde, namelijk de 
economische impact van een ziekte (Shigellose). Hoewel dit op zich van 
belang is, levert dit onvoldoende informatie op om voor beleidsmakers als 
leidraad te dienen bij het maken van verzekeringsdekkingsbeslissingen. 
In werkelijkheid moeten beleidsmakers interventies kiezen door 
gelijktijdig rekening te houden met verschillende criteria (zoals 
bijvoorbeeld effectiviteit, rechtvaardigheid of betaalbaarheid). In 
Thailand heeft dit geleid tot belangstelling voor het gebruik van 
multi-criteria decision analysis (MCDA) voor het stellen van prioriteiten 
binnen de gezondheidzorg.  
2.  Hoe wordt MCDA in Thailand ingevoerd? Specifiek: 
 a) hoe worden prioriteringscriteria geformuleerd?; 
 b) Hoe zouden gezondheidsinterventies in een rangorde moeten 
  worden geplaatst?; en 
 c) wat zijn de uitdagingen binnen het invoeringsproces van MCDA?
MCDA werd gebruikt als overkoepelend model in twee casestudies: om 
prioriteiten te stellen in het bedwingen van HIV/AIDS (Hoofdstuk 4 en 5); 
en om het basispakket te definiëren in de universele basisdekking  in 
Thailand (Hoofdstuk 6).
Hoofdstuk 4 identificeert criteria voor het prioriteren van HIV/AIDS 
interventies in Thailand, vanuit het perspectief van de beleidsmakers, 
mensen die leven met HIV/AIDS  en leden van een gemeenschap die 
worden vertegenwoordigd door gezondheidsvrijwilligers uit dorpen. Op 
basis hiervan werden discrete choice expiriments (DCE) ontworpen  om 
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het belang van de verschillende criteria voor het stellen van prioriteiten 
onder de 28 beleidsmakers, 74 mensen die leven met HIV/AIDS en 50 
gezondheidsvrijwilligers te bepalen. Het resultaat hiervan liet zien dat 
de belanghebbenden verschillende voorkeuren hebben voor deze criteria 
(d.w.z. de doelgroep van de interventies, geslacht van de doelgroep, het 
type interventie, de effectiviteit en de kwaliteit van de bewijs van de 
effectiviteit). De bevindingen van Hoofdstuk 4 zijn gebruikt om 40 HIV/ 
AIDS interventies in Hoofdstuk 5 te prioriteren. Dit hoofdstuk heeft 
de haalbaarheid van MCDA voor het prioriteren van HIV/AIDS interventies 
in Thailand beschreven door expliciet een overleg te integreren, om zo 
belanghebbende over de rangorde te laten nadenken en deze waar nodig 
 aan te passen. Dit laat ook het nut van overleg als een geïntegreerd 
onderdeel van MCDA zien. 
Hoofdstuk 6 beschrijft de eerste ervaring met het toepassen van 
MCDA als een algemene methodologische aanpak voor het ontwikkelen 
van een universeel basispakket in Thailand, in het periode 2009-2010. 
MCDA werd gebruikt in de verschillende stappen binnen de casestudie 
om prioriteringscriteria te identificeren (voor het selecteren en beoordelen 
van interventies), om een performance matrix te construeren en uit 
te werken, alvorens tot een eind conclusie te komen wat betreft dekking 
van gezondheidsinterventies in het universele basispakket. Met behulp 
van het accountability for reasonableness (A4R) model hebben we het 
project geëvalueerd en gevonden dat MCDA aanzienlijk heeft bijgedragen 
aan een rationele, transparante en eerlijke prioritering. 
In Hoofdstuk 7 hebben we EVIDEM (Evidence and Value: Impact on Decision 
-Making) geëvalueerd, een instrument dat MCDA gebruikt als het 
conceptuele model met zijn vermogen om prioriteiten te stellen binnen 
een reeks interventies. Vervolgens stelden we een stapsgewijs proces voor 
op basis van de eerste ervaringen met prioriteren in de casestudies in 
Thailand.
Dit proefschrift heeft 3 belangrijke vraagstukken vastgesteld in het 
gebruik van MCDA voor het prioriteren van gezondheidsinterventies: 
thesis-summary.indd   163 4/5/2555   13:21:34
Samenvatting
164
1) vraagstukken gerelateerd aan de methodologie die gebruikt wordt 
voor het identificeren van criteria en het meten van het belang van elk 
criteria (d.w.z. DCE in dit proefschrift); 2) vraagstukken gerelateerd aan 
de informatie die wordt gebruikt voor het construeren van de prestatie 
matrices van de interventies als een component van MCDA; en 3) 
vraagstukken gerelateerd aan de besluitvorming. 
3.  Hoe kan MCDA het best worden gebruikt voor het stellen van 
prioriteiten in Thailand?
Uit de eerste ervaringen met het toepassen van MCDA in LMIC lijkt 
MCDA nuttig voor twee doelen: generaliserend en context-specifiek 
prioriteren van interventies (Hoofdstuk 8). De twee casestudies in het 
proefschrift leveren ruim bewijs dat MCDA daadwerkelijk nuttig is om 
generaliserende, grove indelingen van interventies op een specifiek 
ziektegebied te maken (Hoofdstuk 4 en 5), om als leidraad te dienen voor 
besluitvormingen over een ruim pakket interventies op nationaal niveau 
(Hoofdstuk 5 en 6), en om als leidraad te dienen voor zeer contextgebonden 
beslissingen over het opnemen van een aantal interventies in het 
basispakket (Hoofdstuk 6). De bevindingen van dit proefschrift hebben 
laten zien dat MCDA veel potentie heeft om te worden gebruikt voor 
expliciete prioriteringsbesluiten die bijdragen aan de transparantie van het 
prioriteringsproces. 
In de Algemene Discussie (Hoofdstuk 9) worden de belangrijkste bevinden 
besproken. Vervolgens biedt het hoofdstuk een aantal praktische aanbev-
elingen en domeinen voor verder onderzoek om de kans op het gebruik 
van MCDA in Thailand te vergroten. Aangezien er geen gouden standaard 
is om de geschiktheid van prioriteringsbesluiten te beoordelen, verwijzen 
we naar het A4R model dat zich concentreert op eerlijke processen. 
Bovendien stellen we op basis van de eerste ervaringen met het toepassen 
 van MCDA in het stellen van prioriteiten in Thailand een stapsgewijs 
prioriteringsproces voor. Dit bevat: i) het samenstellen van een comité 
met relevante belanghebbenden; ii) het verkrijgen van een pakket met 
lokaal belangrijke criteria door het comité te raadplegen; iii) het vaststellen 
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van het relatieve belang van de criteri, dat wil zeggen gewichten, door 
gebruik te maken van DCE en andere technieken; iv) het beoordelen van 
de doelmatigheid van de interventies op basis van de criteria en de 
gewichten; v) het berekenen van de kans dat de interventie wordt 
geselecteerd om in de rangorde te worden opgenomen; vi)  het organiseren 
van een overleg tussen beleidsmakers (op basis van meerdere 
belanghebbenden) om consensus te bereiken over de uiteindelijk 
prioriteringslijst voor gezondheidsinterventies.
De onderzoeken die in dit proefschrift worden gepresenteerd hebben 
MCDA toegepast in een Thaise context en de bevindingen hiervan kunnen 
mogelijk niet worden gegeneraliseerd naar andere contexten. Echter, 
MCDA, als een algemene aanpak, en alle aanbevelingen die in dit 
proefschrift worden gedaan zijn toepasbaar op of aan te passen aan 
andere omstandigheden. 
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